

Mitochondrial disorders : The Essential



2nd quarter 2026



quarterly literature review

carried out by the AFM-Téléthon documentation department

This literature review, carried out based on queries on PubMed® without claiming to be exhaustive, presents a selection of references to medical-scientific articles concerning the field of mitochondrial diseases.



Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Summary

ATAXIE DE FRIEDREICH - <i>FRIEDREICH ATAXIA</i>	3
ATROPHIE OPTIQUE AUTOSOMIQUE DOMINANTE – <i>AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA)</i>	8
ENCEPHALOPATHIE MYO-NEURO-GASTROINTESTINALE - <i>MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY (MNGIE)</i>	10
MALADIE DE CHARCOT-MARIE-TOOTH D'ORIGINE MITOCHONDRIALE – <i>MITOCHONDRIAL CHARCOT-MARIE-TOOTH DISEASE</i>	10
MALADIES LIEES AU GENE ACO2- <i>ACO2-RELATED DISORDERS</i>	12
MALADIE LIEE AU GENE GFM1 – <i>GFM1-RELATED DISORDER</i>	12
MALADIES LIEES AU GENE POLG (INCLUS SANDO, SCAE) - <i>POLG-RELATED DISORDERS (INCLUDED SANDO, SCAE)</i>	12
MELAS	14
MERFF	17
NEUROPATHIE OPTIQUE HEREDITAIRE DE LEBER - <i>LEBER HEREDITARY OPTIC NEUROPATHY (LHON)</i>	17
OPHTALMOPLÉGIE EXTERNE PROGRESSIVE – <i>PROGRESSIVE EXTERNAL OPHTHALMOPLÉGIA (PEO)</i>	21
SYNDROME D'ALPERS-HUTTENLOCHER - <i>ALPERS-HUTTENLOCHER SYNDROME</i>	22
SYNDROME DE BARTH – <i>BARTH SYNDROME</i>	22
SYNDROME DE KEARNS-SAYRE – <i>KEARNS-SAYRE SYNDROME</i>	23
SYNDROME DE LEIGH - <i>LEIGH SYNDROME</i>	24
MALADIES MITOCHONDRIALES (AUTRES) – <i>MITOCHONDRIAL DISORDERS (OTHER)</i>	26

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Ataxie de Friedreich - *Friedreich ataxia*

Ali, A., Cheema, W. A., Nisar, F., Reyaz, U., Saad, M., Talha, M., Sarfraz, S., Butt, A., Shamoon, M., Abdullah, A., Shabbir, M. A., Talha, M., Azam, H., Abdullah, M. et Anwaar, A. (2026). **Slowing the curve: a single-arm meta-analysis of mFARS outcomes following omaveloxolone treatment in Friedreich ataxia.** *BMJ Neurol Open* 8, e001670, doi:[10.1136/bmjno-2026-001670](https://doi.org/10.1136/bmjno-2026-001670).

Ali, S. A. H., Early, J., Farmer, J. M., Gelbard, S., Corben, L., Rance, G. et Lynch, D. R. (2026). **Listening in Spatialized Noise-Sentences (LiSN-S) as a Measure of Auditory Function in Friedreich Ataxia.** *Cerebellum* 25, 60, doi:[10.1007/s12311-026-02000-7](https://doi.org/10.1007/s12311-026-02000-7).

Ansari, F. U., Rojsajjakul, T., Liu, J., Nageshwaran, S. K. et Blair, I. A. (2026). **Epigenetic reactivation in Friedreich's ataxia from benzamides to gene-targeted chimeras.** *Expert Opin Drug Discov* 21, 779-791, doi:[10.1080/17460441.2026.2689723](https://doi.org/10.1080/17460441.2026.2689723).

Brandon, C. J., Robinson-Thiewes, S., Kaulage, M., Rosikiewicz, W., Cuneo, M. J., Brett, J., Kandola, J., Lang, W. H., Low, J., Mohammed, A., Danda, A., Rider, S., Valentine, M., Ochoada, J., Young, B., Nguyen, T., Kietlinska, S. J., Taylor, A. B., Hoeckendorf, B., Rodrigues, P., Lin, W., Khairy, K., Xu, B., Shelat, A. A., Chen, T., Mittag, T. et Ansari, A. Z. (2026). **BRD4 recruitment desilences transcription without erasure or depletion of repressive chromatin.** doi:[10.64898/2026.04.10.717856](https://doi.org/10.64898/2026.04.10.717856).

Buchholz, M., Monier, V., Ewencyk, C., Heinzmann, A., Pierron, L., Sayah, S., Hilab, R., Atencio, M., Petit, E., Bertrand, F., Vallancien, A., Diot, C., Rouillon, S., Nadke, A., Feldmann, K., Maas, V., Faber, J., Sarwinska, D., Boesch, S. M., Indelicato, E., Bischoff, A. T., Klopstock, T., Schulz, J. B., Reetz, K., Fleszar, Z., Iskandar, A., Klockgether, T., Grobe-Einsler, M., Xie, F., Humphries, B., Michalowsky, B., Durr, A. et Borel, S. (2026). **A Patient-Reported Outcome Measure of Communication Difficulties in Friedreich Ataxia: COMATAX.** *Cerebellum* 25, 85, doi:[10.1007/s12311-026-02020-3](https://doi.org/10.1007/s12311-026-02020-3).

Buchinger, D., Scherer, T., Dalos, D. et Milenkovic, I. (2026). **Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.** *CNS Drugs*, doi:[10.1007/s40263-026-01312-w](https://doi.org/10.1007/s40263-026-01312-w).

Campos, J. C. et Ferreira, J. C. B. (2026). **Targeting competitive Fe-S regulation to treat Friedreich's ataxia.** *Trends Pharmacol Sci* 47, 590-593, doi:[10.1016/j.tips.2026.04.010](https://doi.org/10.1016/j.tips.2026.04.010).

Chandra, S., Kwak, C. S., Du, Z., Barisano, G., Nguyen, K. T., Vinogradov, V. et Wang, X. (2026). **Chemical modulation of Miro1 alleviates cell-type-specific vulnerabilities in Friedreich's ataxia.** *Cell Chem Biol* S2451-9456(26)00156-X, doi:[10.1016/j.chembiol.2026.05.004](https://doi.org/10.1016/j.chembiol.2026.05.004).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Chapman, L. R., Mortiboys, H. et Shaw, P. J. (2026). **Recent developments in Friedreich's ataxia: a state-of-the-art review.** Brain Commun 8, fcag143, doi:[10.1093/braincomms/fcag143](https://doi.org/10.1093/braincomms/fcag143).

Crystal, R. G., Weinsaft, J. W., Kaminsky, S. M., Caragiulo, A., Savage, N., Patel, A., Gavrilova, R. H., Perlman, S. L., Galbraith, M., Kahlon, U., Krishnan, U., Kaner, R. J., Sanders, A., Vo, M., Sarva, H., Yoo, A., Sondhi, D., De, B. P., Mezey, J. G., Aubert, G., Khan, A., Selvan, N., Bhalla, N., Adler, E. et Zesiewicz, T. (2026). **AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial.** JAMA Cardiol e261699, doi:[10.1001/jamacardio.2026.1699](https://doi.org/10.1001/jamacardio.2026.1699).

De Toni, F., Hamdani, M., Patadia, C. et Shankar, G. (2026). **Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling.** Clin Transl Sci 19, e70565, doi:[10.1111/cts.70565](https://doi.org/10.1111/cts.70565).

Devore, M. C., Lam, C., Xiao, E., Devore, J., McCain, K. R. C., Wiley, G., Park, C. C., Lynch, D. R. et Bidichandani, S. I. (2026). **FXN protomutations are the source of pathogenic expanded GAA alleles in Friedreich ataxia and explain its unequal population distribution.** Hum Mol Genet 35, ddag046, doi:[10.1093/hmg/ddag046](https://doi.org/10.1093/hmg/ddag046).

DuBreuil, D. M., Fleming, M., Parikh, Y., Woo, M., Bu, J., Ayloo, S., Langohr, I. M., Bangari, D. S., Mueller, C. et Ramachandran, S. (2026). **Development of a secretable frataxin for enhanced efficacy in treating Friedreich's Ataxia.** Mol Ther Adv 34, 201661, doi:[10.1016/j.omta.2025.201661](https://doi.org/10.1016/j.omta.2025.201661).

Eumann, R., Krahe, J., Dogan, I., Costa, A. S., Schulz, J. B., Lischewski, S. A., Reetz, K., et FACROSS Study Group (2026). **Psychological resilience in patients with Friedreich ataxia: a 6-year longitudinal analysis.** Neurol Res Pract 8, 40, doi:[10.1186/s42466-026-00499-z](https://doi.org/10.1186/s42466-026-00499-z).

Galán-Cruz, J., Vicente-Acosta, A., Loría, F., Díaz-Nido, J. et Herranz-Martín, S. (2026). **The TRKB Agonist 7,8-dihydroxyflavone Alleviates DNA Damage and Apoptosis in a Neuronal Cell Model of Friedreich's Ataxia.** Mol Neurobiol 63, 580, doi:[10.1007/s12035-026-05856-2](https://doi.org/10.1007/s12035-026-05856-2).

Georgiev, C., Bourguignon, M., Mongold, S. J., Moumdjian, L., Cabaraux, P. et Naeije, G. (2026). **Anodal cerebellar tDCS does not alter beta oscillations or corticokinematic coherence in Friedreich's ataxia and healthy participants.** Clin Neurophysiol 190, 2111961, doi:[10.1016/j.clinph.2026.2111961](https://doi.org/10.1016/j.clinph.2026.2111961).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Gong, Q., Liu, T., Han, X., Zhang, R., Liu, X., Xiong, B., Ali, T., Huang, J., Xie, Y., Li, S. et Yang, X. (2026). **Autophagy activation by urolithin-a derivative UA-36 mitigates Friedreich's ataxia pathologies induced by frataxin deficiency.** Mol Biomed 7, 82, doi:[10.1186/s43556-026-00457-w](https://doi.org/10.1186/s43556-026-00457-w).

Grabarczyk, Ł. (2026). **Comprehensive Review of Anesthetic Strategies for Patients With Neurodegenerative Diseases.** Med Sci Monit 32, e950453, doi:[10.12659/MSM.950453](https://doi.org/10.12659/MSM.950453).

Ibáñez-Cabellos, J. S., Baviera-Muñoz, R., Alemany-Perna, B., Sivera, R., Bataller, L., Cesar, S., González-Cabo, P., García-Giménez, J. L., Pallardó, F. V. et Seco-Cervera, M. (2026). **Validation of circulating miR-323a-3p and miR-625-3p to classify hypertrophic cardiomyopathy in Friedreich's ataxia.** Sci Rep 16, 15056, doi:[10.1038/s41598-026-50975-4](https://doi.org/10.1038/s41598-026-50975-4).

Iqbal, M. J., Wali, F., Israr, L., Khan, N. U., Farooqi, H. A., Naveed, F., Kabir, A., Morganti, G., Ricci, A. et Menotta, M. (2026). **Trends and Disparities in Mortality from Hereditary Ataxia in United States, 2000-2020: A Retrospective Analysis with Projections to 2050.** Cerebellum 25, 101, doi:[10.1007/s12311-026-02046-7](https://doi.org/10.1007/s12311-026-02046-7).

Iskandar, A., Buchholz, M., Sarwinska, D., Borel, S., Durr, A., Atencio, M., Ewencyk, C., Heinzmann, A., Weber, S., Hilab, R., Xie, F., Humphries, B., Klockgether, T., Grobe-Einsler, M., Maas, V., Feldmann, K., Rouillon, S., Nadke, A., Davies, E. H., Minnerop, M., Erdlenbruch, F., Bischoff, A. T., Klopstock, T., Fleszar, Z., Boesch, S., Indelicato, E., Schulz, J. B., Reetz, K. et Michalowsky, B. (2026). **Transitional Life Events in Friedreich Ataxia: Differential Age at Onset Perspectives.** Cerebellum 25, 96, doi:[10.1007/s12311-026-02038-7](https://doi.org/10.1007/s12311-026-02038-7).

Kang, H.-M., Li, B., Yan, S., Zhang, L.-L., Wan, G.-J., Zhang, J.-Z. et Pan, W.-D. (2026). **Hypomagnetic Field Exposure Alters Iron-Sulfur Homeostasis and Oxidative Balance in a Frataxin-Deficient Insect System.** Insects 17, 373, doi:[10.3390/insects17040373](https://doi.org/10.3390/insects17040373).

Karnay, A., Linares-Saldana, R., Wang, Q., Gardner, Z., Liang, J. A., Santini, G. T., Haridhasapavalan, K. K., Nguyen, S. C., Hugelier, S., Shewale, B., Kanemaki, M. T., Napierala, J. S., Napierala, M., Wilson, R. B., Dubois, N., Poleshko, A., Kim, W., Shah, P. P., Lakadamyali, M., Joyce, E. F. et Jain, R. (2026). **Transcription and cohesin direct domain boundary spatial positioning and are linked to Friedreich's ataxia.** Mol Cell 86, 1911-1930.e11, doi:[10.1016/j.molcel.2026.04.019](https://doi.org/10.1016/j.molcel.2026.04.019).

Kırboğa, K. K. et Küçüksille, E. U. (2026). **Thermodynamic Preference of Fe²⁺ for a C-Terminal Coordination Site in Human Frataxin Revealed by Multiscale Simulations.** J Chem Inf Model 66, 6676-6694, doi:[10.1021/acs.jcim.6c00960](https://doi.org/10.1021/acs.jcim.6c00960).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Koeppen, A. H., Mazurkiewicz, J. E., Feustel, P. J., Pelech, S., Sutter, C., Fu, Q. et Lin, Q. (2026). **A phosphorylated variant of the mast/stem cell growth factor receptor KIT is upregulated in dorsal root ganglia of Friedreich ataxia.** Histol Histopathol 25093, doi:[10.14670/HH-25-093](https://doi.org/10.14670/HH-25-093).

Lawson, R., Natarajan, S., Correll, J. R., Clark, A., Martin, M. L., Bushnell, D. M. et Setyawan, J. (2026). **Exploring US patient and caregiver perspectives on burden associated with Friedreich Ataxia.** J Patient Rep Outcomes 10, 92, doi:[10.1186/s41687-026-01067-4](https://doi.org/10.1186/s41687-026-01067-4).

Lazaropoulos, M. P., Devore, M. C., Lam, C., Park, C., Bidichandani, S. et Lynch, D. R. (2026). **Compound Heterozygote Friedreich Ataxia Patients With Covert Proximal FXN Gene Deletions.** Ann Clin Transl Neurol, doi:[10.1002/acn3.70408](https://doi.org/10.1002/acn3.70408).

Lazaropoulos, M. P. et Lynch, D. R. (2026). **Advances in Gene and Cellular Therapy in Friedreich Ataxia.** Mol Diagn Ther, doi:[10.1007/s40291-026-00854-5](https://doi.org/10.1007/s40291-026-00854-5).

Lees, J. G., Zhang, H., Jiao, L., Kong, A. M., Phang, R. J., Li, L., Su, N., Bass-Stringer, S., Woo, H.-Y. H., Mukhtar, A. S., Pébay, A., Dottori, M., Corben, L., Delatycki, M., Peverill, R., Wilcox, S., Choi, J., Pullin, J. M., McCarthy, D., Napierala, J. S., Napierala, M. et Lim, S. Y. (2026). **Frataxin deficiency drives cardiac dysfunction and transcriptional dysregulation in Friedreich ataxia iPSC model.** Cell Death Dis, doi:[10.1038/s41419-026-09030-3](https://doi.org/10.1038/s41419-026-09030-3).

Lin, K. Y., Bucha, A., McSweeney, K., Wade, K. L., Karaj, A., Tamaroff, J., O'Malley, S., Chung, N. M., Cilenti, N. A., Wanner, J., Adzika, G. K., Mesaros, C., Blair, I. A., Rojsajakul, T., Serai, S., Farmer, J., Bryant, K., Lu, Y., Harhay, M. O., Weber, D. R., Paridon, S. M., Seifert, E. L., Putt, M. E., Zamani, P., Baur, J. A., Lynch, D. R. et McCormack, S. E. (2026). **Safety and efficacy of individualised exercise and NAD⁺ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial.** Lancet Neurol 25, 469-481, doi:[10.1016/S1474-4422\(26\)00082-7](https://doi.org/10.1016/S1474-4422(26)00082-7).

Lyons, S., Kearney, M., Fahey, M. C., Janjal, P., Pandolfo, M. et Patton, P. (2026). **Pharmacological treatments for Friedreich ataxia.** Cochrane Database Syst Rev 5, CD007791, doi:[10.1002/14651858.CD007791.pub5](https://doi.org/10.1002/14651858.CD007791.pub5).

Maccora, S., Quartetti, U., Lima, S. M., Rini, N., Cucchiara, M., Agnello, L., Gambino, C. M., Brighina, F., Ciaccio, M. et Di Stefano, V. (2026). **Neurophysiological assessment of disease severity in Friedreich's Ataxia: a study of brainstem auditory and visual evoked potentials.** Clin Neurophysiol 188, 2111933, doi:[10.1016/j.clinph.2026.2111933](https://doi.org/10.1016/j.clinph.2026.2111933).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Manrique, L., Martínez-Dubarbíe, F., Pelayo-Negro, A. L., Benítez-Calle, N., Sánchez-Pelaez, M. V., Cota-Gonzalez, D., Loza, R., Martínez-Díaz, R., Irure-Ventura, J., Sánchez-Quintana, C., Sánchez, I., Matilla-Dueñas, A. et Infante, J. (2026). **Longitudinal analysis shows GAA1 length and baseline clinical status as robust predictors of progression in Friedreich ataxia.** J Neurol 273, 259, doi:[10.1007/s00415-026-13812-2](https://doi.org/10.1007/s00415-026-13812-2).

Öz, G., Coccozza, S., Rezende, T. J. R., Henry, P.-G., Faber, J., Harding, I. H., et Ataxia Global Initiative Working Group on MRI Biomarkers (2026). **MRI end-points for clinical trials in ataxias: recommendations from the Ataxia Global Initiative MRI Biomarkers Working Group.** Nat Rev Neurol 22, 439-456, doi:[10.1038/s41582-026-01218-7](https://doi.org/10.1038/s41582-026-01218-7).

Petit, E., Sayah, S., Indelicato, E., Borel, S., Grobe-Einsler, M., Faber, J., Bischoff, A. T., Klopstock, T., Schulz, J. B., Reetz, K., Schöls, L., Humphries, B., Atencio, M., Hilab, R., Iskandar, A., Buchholz, M., Xie, F., Klockgether, T., Michalowsky, B., Boesch, S., Durr, A. et Coarelli, G. (2026). **Cerebellar cognitive-affective syndrome in Friedreich Ataxia.** J Neurol 273, 400, doi:[10.1007/s00415-026-13786-1](https://doi.org/10.1007/s00415-026-13786-1).

Pido-Lopez, J., Moula, S. E., Shaban, E., Stamatiou, K., Critchley, B. J., Whittaker, T. E., Svensson, S., Anjomani-Virmouni, S., Kalef-Ezra, E., Carr, L., Hassel, J., Thrasher, A. J., Kurian, M. A., Blair, I. A., Rojsajakul, T., Santilli, G. et Sala, A. (2026). **Therapeutic activity of a hematopoietic stem cell-delivered cell-penetrating frataxin in Friedreich's ataxia models.** Cell Rep Med 7, 102803, doi:[10.1016/j.xcrm.2026.102803](https://doi.org/10.1016/j.xcrm.2026.102803).

Rummey, C., Blair, I. A., Mesaros, C., Rojsajakul, T., Dong, Y., Wilmot, G., Zesiewicz, T., Mathews, K., Hoyle, J. C., Seeberger, L., Corben, L. A., Delatycki, M. B., Finkel, R. S., Roxburgh, R. H., Duquette, A., Yoon, G., Gomez, C. M., Subramony, S. H., Perlman, S., McCormack, S. et Lynch, D. R. (2026). **Peripheral frataxin levels govern long-term clinical progression in Friedreich ataxia.** BMJ Neurol Open 8, e001561, doi:[10.1136/bmjno-2026-001561](https://doi.org/10.1136/bmjno-2026-001561).

Ryu, S., Inman, J., Hong, H., Jovanovic, V. M., Chen, Q., Gedik, Y., Jethmalani, Y., Hur, I., Harouni, M., Voss, T., Lack, J., Collins, J., Ormanoglu, P., Simeonov, A., Tristan, C. A. et Singeç, I. (2026). **Modeling Friedreich's ataxia with Bergmann glia-enriched human cerebellar organoids.** Commun Biol, doi:[10.1038/s42003-026-10180-5](https://doi.org/10.1038/s42003-026-10180-5).

Schultheiß, J., Watkins, B. et Kröger, S. (2026). **Frataxin Expression in Sensory Neurons Is Required for Muscle Spindle Function and Proprioception.** Muscle Nerve 74, 474-484, doi:[10.1002/mus.70311](https://doi.org/10.1002/mus.70311).

Schulz, J. B. et Reetz, K. (2026). **Targeting exercise, energy, or both in Friedreich's ataxia.** Lancet Neurol 25, 435-437, doi:[10.1016/S1474-4422\(26\)00129-8](https://doi.org/10.1016/S1474-4422(26)00129-8).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Smith, B. K., Coker, M. A., Liberati, C., Meyer, B. P., Norman, S., Ehrbar, J., Leon-Astudillo, C., Subramony, S. et Corti, M. (2026). **Assessing airway clearance dysfunction in Friedreich's ataxia: A focus on peak cough flow.** J Neuromuscul Dis 22143602261452334, doi:[10.1177/22143602261452334](https://doi.org/10.1177/22143602261452334).

Tran, M., Ranaweera, K., Ngo, T., Pathirana, P. N., Milne, S. C., Horne, M., Delatycki, M. B. et Corben, L. A. (2026). **Domain Adaptation for IMU Data to Enhance Objective Assessment of Friedreich Ataxia.** IEEE J Biomed Health Inform PP, doi:[10.1109/JBHI.2026.3702417](https://doi.org/10.1109/JBHI.2026.3702417).

Vallortigara, J., Greenfield, J., Hunt, B., Schuman, B.-J., Hoffman, D., Booth, S., Reinhard, C., Graessner, H., Federico, A., Quoidbach, V., Morris, S. et Giunti, P. (2026). **Friedreich's ataxia patient pathway in Europe.** Front Health Serv 6, 1817584, doi:[10.3389/frhs.2026.1817584](https://doi.org/10.3389/frhs.2026.1817584).

Yadav, R. K., Swarup, V., Ahuja, A., Talukdar, D., Garg, D., Aski, M., Srivastava, A. K. et Yadav, P. (2026). **Genetic modifiers of Friedreich's ataxia pathophysiology in Drosophila melanogaster - A systematic review and meta-analysis.** Free Radic Biol Med 254, 196-210, doi:[10.1016/j.freeradbiomed.2026.06.031](https://doi.org/10.1016/j.freeradbiomed.2026.06.031).

Atrophie optique autosomique dominante – Autosomal dominant optic atrophy (ADOA)

Alavi, M. V. (2026). **Targeting the OPA1 pathway in Autosomal Dominant Optic Atrophy (ADOA): 25 years from gene discovery to therapeutic strategy.** Expert Opin Ther Targets 30, 451-461, doi:[10.1080/14728222.2026.2671678](https://doi.org/10.1080/14728222.2026.2671678).

Beaulieu, C., Bouzidi, A., Desquirit-Dumas, V., Dieu, X., Makam, R., Jurkute, N., Vignal, C., Philibert, M., Odent, S., Zanlonghi, X., Latypov, M., Debourdeau, E., Bocquet, B., Yahia, R., Pons, L., Villard, F. P., Jeanjean, L., Verrecchia, S., Froment, C., Engel, C., Poirsier, C., Arndt, C., Dollfus, H., Gohier, P., Charif, M., Ferré, M., Prunier-Mirebeau, D., Meunier, I., Yu-Wai-Man, P., Amati-Bonneau, P., Lenaers, G. et Smirnov, V. (2026). **Clinical and Genetic Spectrum of ACO2-Linked Dominant Optic Atrophy.** JAMA Ophthalmol 144, 452-462, doi:[10.1001/jamaophthalmol.2026.0634](https://doi.org/10.1001/jamaophthalmol.2026.0634).

Giada Giovenale, A. M., Ferrone, I., Tomaselli, S., Turco, E. M., Mazzoni, M., Torres, B., Zanfardino, P., Vulcano, E., Ferrari, D., Damiani, D., Santorelli, F. M., Luca, A. D., Pennuto, M., Vescovi, A. L., Petruzzella, V. et Rosati, J. D. (2026). **Generation and characterization of the hiPSC line CSSi023-A (16154) from a patient with ADOA caused by an OPA1 variant.** Stem Cell Res 94, 104022, doi:[10.1016/j.scr.2026.104022](https://doi.org/10.1016/j.scr.2026.104022).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Jaggers, T. N., Ripolles-Garcia, A., Moshiri, A., Story, B. D., Wang, J., Chen, R., Moore, L. G., Teixeira, L. B. C., Shim, J., Raposo, A. C., Casanova, M. I., Le, S. M., Park, S., Young, L. J., Kim, S., Roszak, K. P., Ureno, V., Karpinen, P. M., Echeverria, N., Ardon, M., Leonard, B. C., Knipe, M., Bliss-Moreau, E., Fortune, B., Stout, J. T., Rogers, J., Marsh-Armstrong, N. et Thomasy, S. M. (2026). **Rhesus macaques with an OPA1 mutation demonstrate features of autosomal dominant optic atrophy.** Proc Natl Acad Sci U S A 123, e2509165123, doi:[10.1073/pnas.2509165123](https://doi.org/10.1073/pnas.2509165123).

Kessel, L., Andersen, M. K., Grønskov, K. et Bertelsen, M. (2026). **A nationwide overview of the clinical and genetic landscape of inherited eye disorders in Denmark.** Ophthalmic Genet 1-8, doi:[10.1080/13816810.2026.2685298](https://doi.org/10.1080/13816810.2026.2685298).

Khan, A. O. (2026). **Pediatric hereditary optic neuropathies in the United Arab Emirates.** Ophthalmic Genet 1-6, doi:[10.1080/13816810.2026.2674280](https://doi.org/10.1080/13816810.2026.2674280).

Khanna, R. K., Cui, X., Wong, D. C. S., Makam, R., Ducloyer, J.-B., Chao de la Barca, J. M., Bocca, C., Vignal-Clermont, C., Blasco, H., Orssaud, C., Reynier, P. et Yu-Wai-Man, P. (2026). **Omics in hereditary optic neuropathies: A systematic review of clinical studies with an integrated point of view.** Surv Ophthalmol S0039-6257(26)00059-7, doi:[10.1016/j.survophthal.2026.04.006](https://doi.org/10.1016/j.survophthal.2026.04.006).

Lee, N. S., Fraser, C. L., Stark, Z. et Ahmad, K. (2026a). **Novel heterozygous UCHL1 variant causing severe optic atrophy and vision loss.** Ophthalmic Genet 1-4, doi:[10.1080/13816810.2026.2655887](https://doi.org/10.1080/13816810.2026.2655887).

Lee, N. S., Grigg, J. R., Stark, Z. et Ahmad, K. (2026b). **UCHL1-Related Dominant Optic Atrophy: Report of Two New Families.** Neuroophthalmology 50, 381-386, doi:[10.1080/01658107.2025.2548315](https://doi.org/10.1080/01658107.2025.2548315).

Schrittwieser, J., Reitner, A., Kircher, K., Bertich, M., Stapf, C., Lilja, S. V., Paquay, A., Reiter, G. S., Bittner, R. E., Schmidt, W. M. et Pemp, B. (2026). **Impact of Inner Retinal Layer Thinning on Visual Function in OPA1 Autosomal Dominant Optic Atrophy and Associations With Age and Genetic Variant Class.** Invest Ophthalmol Vis Sci 67, 13, doi:[10.1167/iovs.67.4.13](https://doi.org/10.1167/iovs.67.4.13).

Van de Vondel, L., Lee, G. S., De Winter, J., Matsuzaki, S., Sandoval, A., Ramirez, J. F., Monticelli, A., Lee, S., Horvath, R., de Bleecker, J., Züchner, S., Humphries, K. M., Baets, J. et Yoon, W. H. (2026). **Heterozygous OGDH Variants Are Involved in Peripheral Neuropathy With Ataxia and Optical Atrophy.** JIMD Rep 67, e70103, doi:[10.1002/jmd2.70103](https://doi.org/10.1002/jmd2.70103).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Volk, M., Maver, A., Vidmar, M. J., Trošt, N., Višnjar, T., Fakin, A., Kovač, L., Habjan, M. Š., Malinar, L., Pajić, S. P., Jerman, U. D., Romih, R., Hawlina, M. et Peterlin, B. (2026). **Discovery of PHB1 as a Novel Candidate Gene in Dominant Optic Atrophy.** Clin Genet 110, 165-171, doi:[10.1111/cge.70174](https://doi.org/10.1111/cge.70174).

Encéphalopathie myo-neuro-gastrointestinale - Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)

Bianchini, A., Boschetti, E., Vitale, G., Adamo, A., Prosperi, E. et Siniscalchi, A. (2026). **Ultrasound assessment of diaphragmatic structure and function before and after orthotopic liver transplantation in MNGIE.** J Ultrasound, doi:[10.1007/s40477-026-01158-4](https://doi.org/10.1007/s40477-026-01158-4).

Li, L., Chen, X., Li, H., Guo, K., Zhang, T., Ma, M. et Zhao, S. (2026). **Association of a Homozygous TYMP c.131G>C Variant With MNGIE in a Chinese Pedigree: Insights From Genetic Analysis and Computational Modeling.** Mol Genet Genomic Med 14, e70253, doi:[10.1002/mgg3.70253](https://doi.org/10.1002/mgg3.70253).

Xia, Y., She, Y., Zhao, R. et Zhang, Y. (2026). **MNGIE with TYMP and POLG variants presenting as decade-long capsule retention: A case report.** Neurol Sci 47, 521, doi:[10.1007/s10072-026-09131-z](https://doi.org/10.1007/s10072-026-09131-z).

Maladie de Charcot-Marie-Tooth d'origine mitochondriale – Mitochondrial Charcot-Marie-Tooth disease

Abati, E., Saccomanno, D., Alberti, C., Anastasia, A., Gagliardi, D., Ferri, E., Arosio, B., D Angelo, G., Cima, R., Bassi, M. T., Oldoni, S., Comi, G. P., Rizzo, F. et Corti, S. P. (2026). **Investigating the role of serum NfL, FGF21, NCAM1 and GDF15 as disease biomarkers for Charcot-Marie-Tooth type 2A.** Sci Rep 16, 16259, doi:[10.1038/s41598-026-49537-5](https://doi.org/10.1038/s41598-026-49537-5).

Ando, M., Okamoto, Y., Higuchi, Y., Yuan, J.-H., Yoshimura, A., Yano, C., Nagatomo, R., Hobara, T., Kojima, F., Hiramatsu, Y., Nozuma, S., Sakiyama, Y. et Takashima, H. (2026). **Arginine ameliorates motor and survival deficits in MFN2-Deficient Drosophila models.** Neurotherapeutics 23, e00900, doi:[10.1016/j.neurot.2026.e00900](https://doi.org/10.1016/j.neurot.2026.e00900).

Cantarero, L., Roldán, M., Rodríguez-Sanz, M., Mathison, A. J., Olivares-Fuentes, M., Díaz-Osorio, Y., Pijuan, J., Frías, M., Urrutia, R., Hoenicka, J. et Palau, F. (2026). **GDAP1 orchestrates redox signaling at membrane contact sites to preserve axonal integrity in Charcot-Marie-Tooth disease.** Neurobiol Dis 227, 107512, doi:[10.1016/j.nbd.2026.107512](https://doi.org/10.1016/j.nbd.2026.107512).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Cao, L., Liu, Y., Li, J., Xia, X. et Zhao, G. (2026). **Research Trends and Insights of Charcot-Marie-Tooth Disease (CMT): A Visualization Analysis (2000-2025)**. Health Sci Rep 9, e72042, doi:[10.1002/hsr2.72042](https://doi.org/10.1002/hsr2.72042).

Ferrer, M., Pedrón, M., Soriano, O., Martínez-Julvez, M., Marín-Baquero, M., García-Villanueva, R., Velázquez-Campoy, A., Marco-Brualla, J., Ripollés-Yuba, C., Fernández-Silva, P., Medina, M., Miramar, M. D., Bestué, M., Moreno-Loshuertos, R. et Ferreira, P. (2026). **Clinical and molecular characterization of a novel pathogenic AIFM1 E336K mutation connecting mitochondrial dysfunction and neurodegeneration**. Cell Commun Signal 24, 313, doi:[10.1186/s12964-026-02862-8](https://doi.org/10.1186/s12964-026-02862-8).

Gharebaghian, H., Ravanbod, M., Ghasemi, A., Okhovat, A. A., Nafissi, S. et Alavi, A. (2026). **Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families**. Rev Neurol (Paris) S0035-3787(26)00528-X, doi:[10.1016/j.neurol.2026.04.008](https://doi.org/10.1016/j.neurol.2026.04.008).

Gupta, S. et Rukadikar, C. A. (2026). **Novel Heterozygous Variant in a Child with Axonal Charcot-Marie-Tooth disease**. Ann Afr Med, doi:[10.4103/aam.aam_241_26](https://doi.org/10.4103/aam.aam_241_26).

Inmongkol, C., Vorasan, N., Limpaninlach, S., Sereephaowong, N., Kulsirichawaroj, P., Sanmaneechai, O. et Burns, J. (2026). **Axonal-demyelinating differences in functional change in pediatric Charcot-Marie-Tooth and related neuropathies**. BMC Neurol 26, 358, doi:[10.1186/s12883-026-04888-4](https://doi.org/10.1186/s12883-026-04888-4).

Lagos, D., de Santiago, P. R., Pérez-Bravo, N., Cartes-Saavedra, B., Vial-Brizzi, J., Troncoso-Chandía, D., Podmanicky, O., Horvath, R. et Eisner, V. (2026). **Disease-causing MFN2 mutants impair mitochondrial fission dynamics by distinct DRP1 dysregulation**. Cell Death Dis, doi:[10.1038/s41419-026-08838-3](https://doi.org/10.1038/s41419-026-08838-3).

Lee, H.-Y., Cheng, W.-L., Pan, S.-H., Lee, C.-J., Wei, Y.-H. et Liu, C.-S. (2026). **De Novo MFN2 p.Arg95Met in Severe Charcot-Marie-Tooth Disease Type 2A**. J Peripher Nerv Syst 31, e70136, doi:[10.1111/jns.70136](https://doi.org/10.1111/jns.70136).

Tessier, M., Hamze, Z., Bonello-Palot, N., Roeckel-Trévisiol, N., Da Silva, N., Verlet, I., Broucqsaault, N., Bertaux, K., Delmont, E., Attarian, S., Bartoli, M., Delague, V., Schneider, B. L. et Bernard-Marissal, N. (2026). **Restoring the interplay between the endoplasmic reticulum and mitochondria by gene therapy improves Charcot-Marie-Tooth type 2A disease**. Proc Natl Acad Sci U S A 123, e2530774123, doi:[10.1073/pnas.2530774123](https://doi.org/10.1073/pnas.2530774123).

Theuriet, J., Ribault, S., Fontaine, F., Gueguen, N., Jacquier, A., Quadrio, I., Dmitrievsky, Z., Konyukh, M., Bonneau, D., Allouche, S., Cassereau, J., Verny, C., Guillet-Pichon, V. et Pegat, A. (2026). **COQ7-Related Neuropathy: Two New Cases and Review of the Literature**. J Peripher Nerv Syst 31, e70132, doi:[10.1111/jns.70132](https://doi.org/10.1111/jns.70132).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Maladies liées au gène ACO2 - ACO2-related disorders

Beaulieu, C., Bouzidi, A., Desquret-Dumas, V., Dieu, X., Makam, R., Jurkute, N., Vignal, C., Philibert, M., Odent, S., Zanolghi, X., Latypov, M., Debourdeau, E., Bocquet, B., Yahia, R., Pons, L., Villard, F. P., Jeanjean, L., Verrecchia, S., Froment, C., Engel, C., Poirsier, C., Arndt, C., Dollfus, H., Gohier, P., Charif, M., Ferré, M., Prunier-Mirebeau, D., Meunier, I., Yu-Wai-Man, P., Amati-Bonneau, P., Lenaers, G. et Smirnov, V. (2026). **Clinical and Genetic Spectrum of ACO2-Linked Dominant Optic Atrophy**. JAMA Ophthalmol 144, 452-462, doi:[10.1001/jamaophthalmol.2026.0634](https://doi.org/10.1001/jamaophthalmol.2026.0634).

Johannesen, K. M., Grønskov, K., Kessel, L., Holstein, S. L. von, Møller, L. B., Andersen, M. K. G., Khinchi, M. S., Hamann, S., Wegener, M. et Bertelsen, M. (2026). **Diagnostic Yield and Clinical Impact of Comprehensive WES/WGS Testing Beyond Common Genetic Causes in Hereditary Optic Atrophy**. Clin Genet, doi:[10.1111/cge.70203](https://doi.org/10.1111/cge.70203).

Khan, A. O. (2026). **Pediatric hereditary optic neuropathies in the United Arab Emirates**. Ophthalmic Genet 1-6, doi:[10.1080/13816810.2026.2674280](https://doi.org/10.1080/13816810.2026.2674280).

Maladie liée au gène GFM1 – GFM1-related disorder

Molina-Berenguer, M., Herrero-Martínez, D., Vallbona-Garcia, A., Vila-Julà, F., Cámara, Y., Vales, Á., González-Aseguinolaza, G., Torres-Torronteras, J. et Martí, R. (2026). **Systemic delivery of AAV-GFM1 corrects COXPD1 molecular alterations in Gfm1R671C/- mice**. EMBO Mol Med 18, 2152-2179, doi:[10.1038/s44321-026-00426-4](https://doi.org/10.1038/s44321-026-00426-4).

Maladies liées au gène POLG (inclus SANDO, SCAE) - POLG-related disorders (included SANDO, SCAE)

Al Mutairi, F., Joueidi, F., Al Mutairi, Z. A., Alshalan, M., Eyaid, W., Mushiba, A. M., AlGhamdi, M., Tabarki, B., AlGhamdi, A., AlTassan, R., Alzaidan, H., Sharif, A., Aldhalaan, H., Umair, M. et Alfadhel, M. (2026). **POLG-related disorders: Clinical and molecular Spectrum in the Saudi population**. Mol Genet Metab Rep 47, 101322, doi:[10.1016/j.ymgmr.2026.101322](https://doi.org/10.1016/j.ymgmr.2026.101322).

Bangel, K. A., Ng, Y., Lim, A., Thomas, N. J. P., Jaiser, S. R., Lai, H. M., Gorman, G. S., Thomas, R. R., Turnbull, D. M., Ramesh, V., Schaefer, A. M., McFarland, R. et Baker, M. R. (2026). **Adjunctive transcranial DC stimulation in the management of refractory drug-resistant focal epilepsy in POLG mitochondrial disease: A case series**. Seizure S1059-1311(26)00139-1, doi:[10.1016/j.seizure.2026.05.009](https://doi.org/10.1016/j.seizure.2026.05.009).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Bingol, I., Umur, O., Sik, S. G., Yilmaz, T. U., Emiroglu, R. et Citak, A. (2026). **Acute Liver Failure following Valproate Exposure in a Teenager with Homozygous POLG c.2243G>C (p.Trp748Ser) Mutation: Late-Onset Presentation and Successful Liver Transplantation - A Case Report.** Mol Syndromol, doi:[10.1159/000552241](https://doi.org/10.1159/000552241).

Burr, S. P., Auckland, K., Glynos, A., Dhawanjewar, A., Ryall, C., Wei, W., Hynes-Allen, A., Prater, M., Sczaniecka-Clift, M., Prudent, J., Chinnery, P. F. et van den Ameele, J. (2026). **MitoPerturb-Seq identifies gene-specific single-cell responses to mitochondrial DNA depletion and heteroplasmy.** Nat Struct Mol Biol 33, 711-723, doi:[10.1038/s41594-026-01779-7](https://doi.org/10.1038/s41594-026-01779-7).

Cheung, A. C. T., Berrahmoune, S., Dassi, C., Pেকেles, H., Gagnon, T., Waters, P. J., Eberhard, R., Buhas, D. et Myers, K. A. (2026). **Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.** Neurotherapeutics 23, e00945, doi:[10.1016/j.neurot.2026.e00945](https://doi.org/10.1016/j.neurot.2026.e00945).

Gonzalez-Carranza, H. R. et Reyes-Vallejo, L. A. (2026). **Paradoxical hypolibido in a hyperandrogenic male with POLG-related mitochondrial disease.** J Sex Med 23, qdag187, doi:[10.1093/jsxmed/qdag187](https://doi.org/10.1093/jsxmed/qdag187).

Tamashiro, H., Ishikawa, K. et Nakada, K. (2026). **Comparative analysis of muscle pathologies and metabolic signaling in mouse models of mitochondrial dysfunction.** Sci Rep 16, 17722, doi:[10.1038/s41598-026-48532-0](https://doi.org/10.1038/s41598-026-48532-0).

Xia, Y., She, Y., Zhao, R. et Zhang, Y. (2026). **MNGIE with TYMP and POLG variants presenting as decade-long capsule retention: A case report.** Neurol Sci 47, 521, doi:[10.1007/s10072-026-09131-z](https://doi.org/10.1007/s10072-026-09131-z).

Yangzom, T., Chen, A., Lundberg, B. C. et Liang, K. X. (2026). **Nicotinamide riboside reduces glial inflammation and boosts mitochondrial function.** Int J Biol Sci 22, 6035-6063, doi:[10.7150/ijbs.119262](https://doi.org/10.7150/ijbs.119262).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

MELAS

Finsterer, J. (2026a). **Commentary: Profiles of paediatric patients experiencing stroke-like episodes associated with mitochondrial disease.** Front Neurol 17, 1775667, doi:[10.3389/fneur.2026.1775667](https://doi.org/10.3389/fneur.2026.1775667).

Finsterer, J. (2026b). **Diagnostic and therapeutic considerations in m.3243A>G-associated chronic intestinal pseudo-obstruction.** Rev Esp Enferm Dig, doi:[10.17235/reed.2026.12026/2026](https://doi.org/10.17235/reed.2026.12026/2026).

Finsterer, J. (2026c). **Whether Metformin Causes Lactic Acidosis in m.3243A>G Carriers Depends on Several Factors.** AACE Endocrinol Diabetes 13, 271-272, doi:[10.1016/j.aed.2025.11.014](https://doi.org/10.1016/j.aed.2025.11.014).

Hathazi, D., Lyons, C., Lagos, D., Podmanicky, O., Zarate-Mendez, M., Nie, Y., Müller, J. S., Allinson, K. S. J., Naylor, H., Lako, M., Elsharkawi, I., Muffels, I., Morava, E., Kozicz, T., Chinnery, P., Lakatos, A. et Horvath, R. (2026). **Mitochondrial DNA heteroplasmy drives cortical neuronal disturbances in human organoids harbouring the common m.3243A>G mutation.** Nat Commun, doi:[10.1038/s41467-026-74103-y](https://doi.org/10.1038/s41467-026-74103-y).

Hayes, E., Nillsen, A., Rowe, P. W., Siafarikas, A. et Abraham, M. B. (2026). **Glucagon-Like Peptide-1 Receptor Agonists in the Management of Mitochondrial Diabetes in an Adolescent: A Case Report.** Horm Res Paediatr 1-9, doi:[10.1159/000552014](https://doi.org/10.1159/000552014).

He, Z., Jiang, H., Li, T., Liu, Y., Zou, Y., Xu, C., Liu, Z., Shen, D., Duan, R., Song, M., Zhang, Y., Zhang, Z., Sun, M., Shen, R., Xue, H. et Fang, F. (2026). **Clinical Spectrum, Heteroplasmy-Phenotype Correlation, and Prognosis of the MT-ND3 m.10191 T > C Mutation.** CNS Neurosci Ther 32, e70997, doi:[10.1002/cns.70997](https://doi.org/10.1002/cns.70997).

Hsu, J. C.-N., Chen, C.-H., Chen, M.-W., Chen, W.-H. et Lee, T.-S. (2026). **The Emerging Role of N-Lactoyl-Phenylalanine (Lac-Phe) in Metabolic Regulation and Disease: From Exercise-Induced Metabolite to Therapeutic Candidate.** Antioxidants (Basel) 15, 441, doi:[10.3390/antiox15040441](https://doi.org/10.3390/antiox15040441).

Hu, J., Liufu, T., Li, C., Zhao, Q., Yu, M., Yuan, Y., Quan, L., Chen, Z. et Wang, Z. (2026). **Detection of NADH/NAD⁺ dysregulation in MELAS via diazo-carboxyl click derivatization mass spectrometry.** Clin Chim Acta 591, 121172, doi:[10.1016/j.cca.2026.121172](https://doi.org/10.1016/j.cca.2026.121172).

Huang, Y.-J. et Lin, W.-S. (2026). **Transient Hemichorea Associated With Mitochondrial Metabolic Stroke.** J Child Neurol 8830738261441098, doi:[10.1177/08830738261441098](https://doi.org/10.1177/08830738261441098).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Jentsch, L. et Ventura, N. (2026). **Mitochondrial complex I deficiency-associated diseases and models**. Cell Mol Life Sci 83, 249, doi:[10.1007/s00018-026-06169-2](https://doi.org/10.1007/s00018-026-06169-2).

Labriffe, M., Amati-Bonneau, P. et Spinazzi, M. (2026). **Melas mimicking hydrocephalus**. Neurol Sci 47, 506, doi:[10.1007/s10072-026-09113-1](https://doi.org/10.1007/s10072-026-09113-1).

Lee, W. (2026). **Response to: Middle-aged woman presenting with new-onset status epilepticus and family history of MELAS syndrome but negative mtDNA testing**. Epileptic Disord, doi:[10.1002/epd2.70259](https://doi.org/10.1002/epd2.70259).

Li, Y., Han, S., Huang, D., Chen, J., Qu, S., Gu, J., Xu, Z., Fu, L., Tang, X. et Qiao, Y. (2026). **Mitochondrial mutation status, symptom prevalence, and neuroimaging characteristics in MELAS: a systematic review and meta analysis**. Orphanet J Rare Dis, doi:[10.1186/s13023-026-04448-6](https://doi.org/10.1186/s13023-026-04448-6).

Liu, G. et Dong, G. (2026). **Paradox of Reversible Vasoconstriction and Stroke-Like Lesions in MELAS: A Multimodal Imaging Sequence**. Stroke 57, e241-e242, doi:[10.1161/STROKEAHA.126.055745](https://doi.org/10.1161/STROKEAHA.126.055745).

Mancuso, M., Bellusci, M., Carelli, V., de Coo, I., Diodato, D., Distelmaier, F., Hikmat, O., Hirano, M., Horvath, R., Karaa, A., Klopstock, T., Koenig, M. K., Kornblum, C., La Morgia, C., Lopriore, P., Martikainen, M. H., McFarland, R., Musumeci, O., Pitceathly, R. D. S., Primiano, G., Rahman, S., Scaglia, F., Schaefer, A., Schiff, M., Semmler, L., Lamperti, C. et Servidei, S. (2026). **Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements**. Eur J Neurol 33, e70588, doi:[10.1111/ene.70588](https://doi.org/10.1111/ene.70588).

Mehri, S. et Finsterer, J. (2026). **Recurrent Miscarriages and Postpartum Heart Failure Can Be Phenotypic Manifestations of the m.3243A>G Variant**. Clin Case Rep 14, e72935, doi:[10.1002/ccr3.72935](https://doi.org/10.1002/ccr3.72935).

Mohsen, M., Juma, S., Saleh, D., Saleh, T., Amayra, A. et Atrash, J. (2026). **From confusion to diagnosis: a rare case of melas syndrome in a patient with familial consanguinity, recurrent stroke-like episodes, and concurrent FSGS**. BMC Neurol 26, 317, doi:[10.1186/s12883-026-04853-1](https://doi.org/10.1186/s12883-026-04853-1).

Nagao, S., Aoki, M., Yatsuga, S., Takeshita, S., Tsuboi, Y. et Uesugi, N. (2026). **Response to: « The Loss and Dysfunction of Smooth Muscle Cells in MELAS Are Not the Only Cause for Gastrointestinal Dysmotility »**. Neurogastroenterol Motil 38, e70306, doi:[10.1111/nmo.70306](https://doi.org/10.1111/nmo.70306).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Oh, J., Lee, K., Won, D., Lee, Y.-M. et Shin, J. I. (2026). **Genetic diagnosis of hereditary kidney disease in pediatric patients through whole-exome sequencing and mitochondrial DNA analysis.** Kidney Res Clin Pract, doi:[10.23876/j.krcp.25.394](https://doi.org/10.23876/j.krcp.25.394).

Picolos, M. K., Papapostolou, A., Christodoulou, A., Tanteles, G. A., Kyriakidou, A. et Papaetis, G. S. (2026). **Clarifications on the report of maternally inherited diabetes and deafness managed with an advanced hybrid closed loop system.** Acta Diabetol, doi:[10.1007/s00592-026-02698-1](https://doi.org/10.1007/s00592-026-02698-1).

Reddy, S. B., Daru, A., Pande, V., Chalipat, S. et Sai, P. B. V. S. (2026). **COQ8A-related Primary Coenzyme Q10 Deficiency Mimicking Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Syndrome: A Pediatric Case Report and Review of Mitochondrial Mimics.** Ann Afr Med, doi:[10.4103/aam.aam_180_26](https://doi.org/10.4103/aam.aam_180_26).

Sharma, G., Srivastava, A., Rockman-Greenberg, C. et Dhingra, S. (2026a). **Generation of a patient-derived iPSC line from a clinically diagnosed MELAS case carrying the mtDNA m.3243A > G variant.** Stem Cell Res 95, 104038, doi:[10.1016/j.scr.2026.104038](https://doi.org/10.1016/j.scr.2026.104038).

Sharma, G., Srivastava, A., Rockman-Greenberg, C. et Dhingra, S. (2026b). **iPSC generation from PBMCs of a MELAS patient for mitochondrial dysfunction studies.** Stem Cell Res 94, 103992, doi:[10.1016/j.scr.2026.103992](https://doi.org/10.1016/j.scr.2026.103992).

Song, K., Yoon, M. K., Yang, W., Chang, J. Y., Kang, D.-W., Kwon, S. U. et Kim, B. J. (2026). **Cerebral vasodilation and lesion patterns in stroke-like episodes of MELAS: a quantitative angiographic investigation.** Quant Imaging Med Surg 16, 361, doi:[10.21037/qims-2025-1-2735](https://doi.org/10.21037/qims-2025-1-2735).

Stern, S., Crisamore, K., Patton, J., Schuck, R. et Pacanowski, M. (2026). **From Pharmacodynamic Biomarker to Evaluating Treatment Response: Biomarkers in Primary Mitochondrial Diseases.** Clin Transl Sci 19, e70634, doi:[10.1111/cts.70634](https://doi.org/10.1111/cts.70634).

Wang, L.-T. et Jhuang, H.-Y. (2026). **Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies.** Biomed Pharmacother 201, 119699, doi:[10.1016/j.biopha.2026.119699](https://doi.org/10.1016/j.biopha.2026.119699).

Wu, H., Wang, Y. et Kong, Q. (2026). **Phenotypic heterogeneity within twins with MELAS with epilepsy: Case report.** Medicine (Baltimore) 105, e47264, doi:[10.1097/MD.00000000000047264](https://doi.org/10.1097/MD.00000000000047264).

Zhang, W., Lian, H., Li, J. et Yang, L. (2026). **Mitochondrial encephalomyopathy with chronic intestinal pseudo-obstruction.** Rev Esp Enferm Dig, doi:[10.17235/reed.2026.11948/2026](https://doi.org/10.17235/reed.2026.11948/2026).



Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

MERFF

Roy, S., Mundlamuri, R. C., Vengalil, S., Raja, P., Atchayaram, N. et Yadav, R. (2026). **Alternating hemispheric focal status epilepticus : An atypical presentation of genetically confirmed case of MERRF syndrome.** *Seizure* 139, 21-24, doi:[10.1016/j.seizure.2026.04.004](https://doi.org/10.1016/j.seizure.2026.04.004).

Wu, Y.-T., Tay, H.-Y., Liao, H.-H., Yang, J.-T. et Wei, Y.-H. (2026). **Role of oxidative stress in the susceptibility to mitophagy of the skin fibroblasts and iPSC-derived neurons of patients with MERRF syndrome.** *Mitochondrion* 91, 102171, doi:[10.1016/j.mito.2026.102171](https://doi.org/10.1016/j.mito.2026.102171).

Neuropathie optique héréditaire de Leber - *Leber hereditary optic neuropathy (LHON)*

Alghamdi, L. N., Alsudais, A. S., Almarwani, S. H., Alraddadi, R. A., Alsamadani, A. H., Alnamlah, A. A., Aljehani, S. K., Allarakia, Y. F., Alghamdi, A. M. et Alshowaeir, D. (2026). **Gene Therapy for Leber Hereditary Optic Neuropathy (LHON): A Systematic Review and Meta-Analysis.** *Neuroophthalmology* 50, 215-221, doi:[10.1080/01658107.2026.2624440](https://doi.org/10.1080/01658107.2026.2624440).

Aljawi, A. A. et Badeeb, N. O. (2026). **Leber hereditary optic neuropathy triggered by the AstraZeneca coronavirus disease 2019 vaccination.** *Oman J Ophthalmol* 19, 137-139, doi:[10.4103/ojo.ojo_431_24](https://doi.org/10.4103/ojo.ojo_431_24).

Amorelli, G., Nilles, C., Pfeffer, G., Joel, M. et Martino, D. (2026). **The m.14484T>C MT-ND6 Mutation Presenting with a Hereditary Spastic-Paraparesis Phenotype.** *Mov Disord Clin Pract*, doi:[10.1002/mdc3.70703](https://doi.org/10.1002/mdc3.70703).

Ashrafkhorasani, M., Chou, B. et Sadun, A. A. (2025). **LEBER HEREDITARY OPTIC NEUROPATHY: A CASE REPORT OF CONCURRENT RARE MITOCHONDRIAL MUTATIONS AND ABCA4 NUCLEAR GENE MUTATION.** *Retin Cases Brief Rep* 19, 647-651, doi:[10.1097/ICB.0000000000001618](https://doi.org/10.1097/ICB.0000000000001618).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Basalem, E. et Badeeb, N. (2026). **Genetic Features and Clinical Heterogeneity of Leber Hereditary Optic Neuropathy in Adolescent and Adult Patients: A Case Series on Arab Patients**. Int Med Case Rep J 19, 571657, doi:[10.2147/IMCRJ.S571657](https://doi.org/10.2147/IMCRJ.S571657).

Buelens, T., Meunier, A., Seneca, S. et Willermain, F. (2026). **Progressive Visual Recovery in a Patient with Leber Hereditary Optic Neuropathy Harboring a Rare Heteroplasmic (MT-ND5):m.13042G>A, p(Ala236Thr) Variant with Low Mutant Load: A Case Report**. Case Rep Ophthalmol 17, 423-432, doi:[10.1159/000551571](https://doi.org/10.1159/000551571).

Choi, H. J., Im, Y. S., Yoon, T., Min, S. H., Song, J. R. et Jung, J. H. (2026). **Generation and characterization of a human induced pluripotent stem cell line (SNUi001-A) harboring the MT-ND4 m.11778G>A mutation**. Stem Cell Res 95, 104043, doi:[10.1016/j.scr.2026.104043](https://doi.org/10.1016/j.scr.2026.104043).

Dewan, L., Pal, S. et Tibrewal, S. (2026). **Letter to the Editor: Comment on Takai et al.'s « Age-Associated Differences in Optic Disc Findings of Leber's Hereditary Optic Neuropathy »**. Neuroophthalmology 50, 292-293, doi:[10.1080/01658107.2026.2642121](https://doi.org/10.1080/01658107.2026.2642121).

Gök, A., Cırdı, G., Deniz, A., Sakarya Güneş, A., Tekin Orgun, L. et Kara, B. (2026). **Leber hereditary optic neuropathy (LHON) in a 6-year-old boy with a transient spinal cord lesion**. Turk J Pediatr 68, 330-336, doi:[10.24953/turkjpdiatr.2026.6882](https://doi.org/10.24953/turkjpdiatr.2026.6882).

Hedström, J., Nilsson, M., Engvall, M., Williams, P. A. et Venkataraman, A. P. (2026). **Health-related quality of life and tobacco and alcohol consumption in Leber hereditary optic neuropathy in Sweden**. Front Ophthalmol (Lausanne) 6, 1791334, doi:[10.3389/fopht.2026.1791334](https://doi.org/10.3389/fopht.2026.1791334).

Jentsch, L. et Ventura, N. (2026). **Mitochondrial complex I deficiency-associated diseases and models**. Cell Mol Life Sci 83, 249, doi:[10.1007/s00018-026-06169-2](https://doi.org/10.1007/s00018-026-06169-2).

Johannesen, K. M., Grønskov, K., Kessel, L., Holstein, S. L. von, Møller, L. B., Andersen, M. K. G., Khinchi, M. S., Hamann, S., Wegener, M. et Bertelsen, M. (2026). **Diagnostic Yield and Clinical Impact of Comprehensive WES/WGS Testing Beyond Common Genetic Causes in Hereditary Optic Atrophy**. Clin Genet, doi:[10.1111/cge.70203](https://doi.org/10.1111/cge.70203).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Khanna, R. K., Cui, X., Wong, D. C. S., Makam, R., Ducloyer, J.-B., Chao de la Barca, J. M., Bocca, C., Vignal-Clermont, C., Blasco, H., Orssaud, C., Reynier, P. et Yu-Wai-Man, P. (2026). **Omics in hereditary optic neuropathies: A systematic review of clinical studies with an integrated point of view.** *Surv Ophthalmol* S0039-6257(26)00059-7, doi:[10.1016/j.survophthal.2026.04.006](https://doi.org/10.1016/j.survophthal.2026.04.006).

Lapshin, E. V., Egorov, A. D., Malogolovkin, A. S., Gasanov, N. B., Smirnikhina, S. A., Tabakov, V. Y. et Karabelsky, A. V. (2026). **Optimized ND4 allotopic expression for gene therapy of Leber's hereditary optic neuropathy.** *Front Bioeng Biotechnol* 14, 1765995, doi:[10.3389/fbioe.2026.1765995](https://doi.org/10.3389/fbioe.2026.1765995).

Li, H. et Micieli, J. (2026). **Leber Hereditary Optic Neuropathy in the Elderly: A Case Report.** *Case Rep Ophthalmol* 17, 305-311, doi:[10.1159/000551146](https://doi.org/10.1159/000551146).

Maximov, V. V., Shebanov, N., Nikitchina, N., Rapoport, R., Maor, Y., Tarassov, I., Pines, O. et Entelis, N. (2026). **Mitochondrial genome microhomology-mediated editing by donor DNA delivery into mitochondria in human cells.** *Mol Ther Nucleic Acids* 37, 102959, doi:[10.1016/j.omtn.2026.102959](https://doi.org/10.1016/j.omtn.2026.102959).

Özdemir, H. N., Özerol, R., Durmaz, A., Aykut, A. et Çelebisoy, N. (2026). **Leber's Hereditary Optic Neuropathy from a Rare Variant, m.3700 G > A, in the MT-ND1 Gene in a Family.** *Neuroophthalmology* 50, 378-380, doi:[10.1080/01658107.2025.2547404](https://doi.org/10.1080/01658107.2025.2547404).

Sikorska, J., Krawczyński, M. R., Korwin, M., Ołdak, M., Bartnik, E., Tońska, K. et Piotrowska-Nowak, A. (2026). **Analysis of genetic risk factors for Leber hereditary optic neuropathy in the Polish population.** *J Appl Genet*, doi:[10.1007/s13353-026-01090-7](https://doi.org/10.1007/s13353-026-01090-7).

Takai, Y., Yamagami, A., Inoue, K., Ishikawa, H., Takahashi, T. et Tanaka, K. (2026a). **Nasal-Predominant Ganglion Cell-Inner Plexiform Layer Thinning Distinguishes Early-Stage Leber Hereditary Optic Neuropathy From Acute Optic Neuritis.** *Clin Exp Ophthalmol*, doi:[10.1111/ceo.70130](https://doi.org/10.1111/ceo.70130).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Takai, Y., Yamagami, A., Inoue, K., Ishikawa, H. et Wakakura, M. (2026b). **Branch retinal vein occlusion in Leber hereditary optic neuropathy with onset at age 50 years or older: frequency and clinical characteristics.** Jpn J Ophthalmol, doi:[10.1007/s10384-026-01364-x](https://doi.org/10.1007/s10384-026-01364-x).

Takai, Y., Yamagami, A., Inoue, K., Yasumoto, R. et Ishikawa, H. (2026c). **Interpreting relative afferent pupillary defect in Leber hereditary optic neuropathy using interocular visual acuity difference.** Ophthalmologica 1-18, doi:[10.1159/000553194](https://doi.org/10.1159/000553194).

Takai, Y., Yamagami, A., Iwasa, M., Inoue, K., Yasumoto, R., Ishikawa, H. et Wakakura, M. (2026d). **Clinical features and temporal trends in a large Japanese LHON cohort, 1995-2024: a retrospective study.** Eye (Lond), doi:[10.1038/s41433-026-04561-7](https://doi.org/10.1038/s41433-026-04561-7).

Takai, Y., Yamagami, A., Iwasa, M., Inoue, K., Yasumoto, R., Ishikawa, H. et Wakakura, M. (2026e). **Reply To: Comments on « Age-Associated Differences in Optic Disc Findings of Leber's Hereditary Optic Neuropathy ».** Neuroophthalmology 50, 294-295, doi:[10.1080/01658107.2026.2642123](https://doi.org/10.1080/01658107.2026.2642123).

Takai, Y., Yamagami, A., Iwasa, M., Inoue, K., Yasumoto, R., Ishikawa, H. et Wakakura, M. (2026f). **Ten-year natural history of visual function in Japanese patients with Leber hereditary optic neuropathy: A retrospective cohort study.** PLoS One 21, e0348093, doi:[10.1371/journal.pone.0348093](https://doi.org/10.1371/journal.pone.0348093).

Wang, K., Li, S., Zhang, Y. et Guan, M. (2026). **[The « Triple-hit » pathogenic mechanism of Leber hereditary optic neuropathy].** Zhejiang Da Xue Xue Bao Yi Xue Ban 1-9, doi:[10.3724/zdxbyxb-2025-0868](https://doi.org/10.3724/zdxbyxb-2025-0868).

Wang, L.-T. et Jhuang, H.-Y. (2026). **Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies.** Biomed Pharmacother 201, 119699, doi:[10.1016/j.biopha.2026.119699](https://doi.org/10.1016/j.biopha.2026.119699).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Welten, A., Algodí, H. S., Abraha, L. et Malvankar-Mehta, M. S. (2026). **Examining the impact on quality-of-life of those living with inherited optic neuropathies: an updated systematic review.** Can J Ophthalmol S0008-4182(26)00154-7, doi:[10.1016/j.cjco.2026.04.010](https://doi.org/10.1016/j.cjco.2026.04.010).

Xi, L., Li, J., Chen, X. et Fei, W. (2026). **A case report of atypical optic neuritis.** Zhong Nan Da Xue Xue Bao Yi Xue Ban 51, 350-358, doi:[10.11817/j.issn.1672-7347.2026.240683](https://doi.org/10.11817/j.issn.1672-7347.2026.240683).

Yu-Wai-Man, P., Newman, N. J., Carelli, V., Biousse, V., Pierache, A., Montestruc, F., Taiel, M. et Sahel, J.-A. (2026). **Efficacy of lenadogene nolparvovec gene therapy versus idebenone in Leber hereditary optic neuropathy due to the m.11778G>A MT-ND4 variant: two matching adjusted indirect comparisons.** Br J Ophthalmol bjo-2025-329206, doi:[10.1136/bjo-2025-329206](https://doi.org/10.1136/bjo-2025-329206).

Ophtalmoplégie externe progressive – Progressive external ophthalmoplegia (PEO)

Amaro, T., Bueno, S., Guirã, C., Filho, H. et Scanavacca, M. (2026). **Progressive Conduction Disease in a Mitochondrial Disorder.** JACC Case Rep 107749, doi:[10.1016/j.jaccas.2026.107749](https://doi.org/10.1016/j.jaccas.2026.107749).

Okletey, J., Muench, M., Yu, C., Maresca, A., Carelli, V. et Tigano, M. (2026). *Mutations Causative of CPEO Differentially Engage Innate Immunity Sensors,* doi:[10.64898/2026.05.24.727547](https://doi.org/10.64898/2026.05.24.727547).

Siragusa, S. L., Blando, S., Fiorini, C., Pasti, A. P., Ormanbekova, D., Casadei, F., Morandi, L., Pegoraro, E., Liguori, R., Carelli, V., La Morgia, C., Caporali, L. et Valentino, M. L. (2026). **Expanding the landscape of tRNA pathogenic variants in mitochondrial DNA.** Brain Commun 8, fcag178, doi:[10.1093/braincomms/fcag178](https://doi.org/10.1093/braincomms/fcag178).

Yoshida, C., Kubota, A., Kawamoto, N., Takahashi, K., Yano, S., Komaki, S., Maeda, M., Naruse, H., Matsukawa, T., Hamada, M., Satake, W. et Toda, T. (2026). **A de novo TWNK Variant Mimicked Sporadic Chronic Progressive External Ophthalmoplegia.** Intern Med, doi:[10.2169/internalmedicine.7395-26](https://doi.org/10.2169/internalmedicine.7395-26).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Syndrome d'Alpers-Huttenlocher - *Alpers-Huttenlocher syndrome*

Bingol, I., Umur, O., Sık, S. G., Yilmaz, T. U., Emiroglu, R. et Citak, A. (2026). **Acute Liver Failure following Valproate Exposure in a Teenager with Homozygous POLG c.2243G>C (p.Trp748Ser) Mutation: Late-Onset Presentation and Successful Liver Transplantation - A Case Report.** Mol Syndromol, doi:[10.1159/000552241](https://doi.org/10.1159/000552241).

Syndrome de Barth – *Barth syndrome*

Bedoyan, J. K. et Vockley, J. (2026). **Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?** Cell Metab 38, 1079-1080, doi:[10.1016/j.cmet.2026.04.014](https://doi.org/10.1016/j.cmet.2026.04.014).

Flavin, B., Vernon, H. J., Todd Cade, W., Contreras, Z., Kobernick, M., Rahman, F., Richardson, T. et Wolff, D. (2026). **AMCP Market Insights: Managed care considerations in Barth syndrome.** J Manag Care Spec Pharm 32, S1-S10, doi:[10.18553/jmcp.2026.32.7-b.s1](https://doi.org/10.18553/jmcp.2026.32.7-b.s1).

Fu, K., Huang, Y., Bowen, V., McCurdy, K., Tan, R. B., Phoon, C. K. L., Marjoram, L. et Dahlen, A. (2026). **Survival and Clinical Progression in Barth Syndrome: Insights From the Barth Syndrome Foundation's Database of 502 Affected Individuals.** J Inherit Metab Dis 49, e70189, doi:[10.1002/jimd.70189](https://doi.org/10.1002/jimd.70189).

Hatch, G. (2026). **Does the beta subunit of mitochondrial trifunctional protein modulate monolysocardiolipin acylation to cardiolipin?** Biochem Cell Biol, doi:[10.1139/bcb-2026-0094](https://doi.org/10.1139/bcb-2026-0094).

Kajese, E., Hachmann, M., Ermer, K. J., Erk, M., Alhasaan, L., Kohlhaas, M., Bömmel, H., Berberich, L., Carlein, C., Eberl, H., Streckfuß-Bömeke, K., Roma, L. P., Ergün, S., Maack, C., Karnati, S. et Dudek, J. (2026). **Peroxisomal catalase and plasmalogen biosynthesis protect from oxidative stress in Barth syndrome cardiomyopathy.** Basic Res Cardiol, doi:[10.1007/s00395-026-01197-2](https://doi.org/10.1007/s00395-026-01197-2).

Kuentzel, K. B., Vranešević, A., Trammell, S. A., Finger, F., Havelund, J. F., Schooneveldt, Y. L., Bradić, I., Andersen, N. R., Hassing, A. S., Michler, K. T., Larsen, M. R., Gerhart-Hines, Z., Claypool, S. M., Treebak, J. T., Fritzen, A. M., Gillum, M. P., Larsen, S., Færgeman, N. et Grevengoed, T. J. (2026). **Omega-3 fatty acid supplementation improves skeletal muscle mitochondrial function in a model of Barth syndrome.** JCI Insight e196134, doi:[10.1172/jci.insight.196134](https://doi.org/10.1172/jci.insight.196134).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Regina, A., Solagna, F., Estrada, M. S., Jacobs, M. M. E., Martinez-Martinez, D., Georgomanolis, T., Alibashikj, I., Gjurgji, S., Pearson, C., Chang, D., Moschandrea, C., Aparisi, A. S., Crespo, E., Buechel, J., Schneider, F., Trojahn, L., Pflzer, P., Popovic, M., Potenza, E., Kabat, A. M., Niessen, C., Amulic, B., Safinia, N., Cogliati, S., Sanin, D. E., Villa, M., Pearce, E. J., Frezza, C., Pearce, E. L., Cabreiro, F., Powrie, F. et Corrado, M. (2026). **Cardiolipin preserves Treg metabolic fitness and immune homeostasis in the gut.** *Nat Metab* 8, 1368-1389, doi:[10.1038/s42255-026-01533-9](https://doi.org/10.1038/s42255-026-01533-9).

Stern, S., Crisamore, K., Patton, J., Schuck, R. et Pacanowski, M. (2026). **From Pharmacodynamic Biomarker to Evaluating Treatment Response: Biomarkers in Primary Mitochondrial Diseases.** *Clin Transl Sci* 19, e70634, doi:[10.1111/cts.70634](https://doi.org/10.1111/cts.70634).

Venkatraman, K., Milshteyn, D., Sarto, C., Kocharian, E., Sakurai, C. M., Armando, A. M., Wong, A. M., Dennis, E. A., Fang, X., Lee, C. T. et Budin, I. (2026a). **Saturated cardiolipins are potent disruptors of inner mitochondrial membrane structure and function.** *J Biol Chem* 113306, doi:[10.1016/j.jbc.2026.113306](https://doi.org/10.1016/j.jbc.2026.113306).

Venkatraman, K., Milshteyn, D., Sarto, C., Kocharian, E., Sakurai, C. M., Armando, A. M., Wong, A. M., Dennis, E. A., Fang, X., Lee, C. T. et Budin, I. (2026b). *Saturated cardiolipins are potent disruptors of inner mitochondrial membrane structure and function*, doi:[10.64898/2026.04.14.718012](https://doi.org/10.64898/2026.04.14.718012).

Wang, L.-T. et Jhuang, H.-Y. (2026). **Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies.** *Biomed Pharmacother* 201, 119699, doi:[10.1016/j.biopha.2026.119699](https://doi.org/10.1016/j.biopha.2026.119699).

Wolf, A., Montanelli, G., Mathis, D., Felser, A., Laemmle, A., Nuoffer, J.-M., Gautschi, M., Bourquin, C. et Stojkov, D. (2026). **Insights into Neutrophil Dysfunction in Inherited Metabolic Disorders.** *J Innate Immun* 18, 233-259, doi:[10.1159/000552119](https://doi.org/10.1159/000552119).

Syndrome de Kearns-Sayre – *Kearns-Sayre syndrome*

Amaro, T., Bueno, S., Guirã, C., Filho, H. et Scanavacca, M. (2026). **Progressive Conduction Disease in a Mitochondrial Disorder.** *JACC Case Rep* 107749, doi:[10.1016/j.jaccas.2026.107749](https://doi.org/10.1016/j.jaccas.2026.107749).



Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Syndrome de Leigh - Leigh syndrome

Akyüzlüer Güneş, M. S., Duman, D., Şen, E. K., Yıldırım, M., Özsu, E., Erdeve, Ö., Kaynak Şahap, S., Eminoğlu, F. T. et Köse, E. (2026). **Two Siblings with LRPPRC Mutation: Mitochondrial Complex IV Deficiency: Case Report.** Mol Syndromol 17, 288-295, doi:[10.1159/000548731](https://doi.org/10.1159/000548731).

Basan, H., Kurt, E. E. et Kasapkara, Ç. S. (2026). **An Atypical Neurosensory-Predominant Presentation Associated with a Homozygous NDUFS3 Variant: A Diagnostic Challenge Involving Retinal and Hearing Phenotypes.** Mol Syndromol, doi:[10.1159/000551507](https://doi.org/10.1159/000551507).

Bedoyan, J. K. et Vockley, J. (2026). **Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?** Cell Metab 38, 1079-1080, doi:[10.1016/j.cmet.2026.04.014](https://doi.org/10.1016/j.cmet.2026.04.014).

Geng, M., Wang, D., Kavoosi, S., Kaufman, B. A. et Sondheimer, N. (2026). **DNM1L depletion leads to accelerated heteroplasmy shifting of m.10191C allele through ATG7-dependent pathways.** Mitochondrion 91, 102185, doi:[10.1016/j.mito.2026.102185](https://doi.org/10.1016/j.mito.2026.102185).

Hanaford, A. R., Olkhova, E. A., Liao, R., Ching, A., Huang, A., Hsieh, E. S., Watanabe, K., Chen, Y., Wichman, M., Hwang, N., James, K., Mulholland, M., Truong, V., Coulson, H., Gibbins, K., Cairns, O., Dimitriou, A., Kayser, B., Johnson, B. M., Sarkar, S., Kalia, V. et Johnson, S. C. (2026). **MyD88 deficiency modestly attenuates disease in a Leigh syndrome mouse model while enrofloxacin accelerates disease.** doi:[10.64898/2026.05.13.724988](https://doi.org/10.64898/2026.05.13.724988).

He, Z., Jiang, H., Li, T., Liu, Y., Zou, Y., Xu, C., Liu, Z., Shen, D., Duan, R., Song, M., Zhang, Y., Zhang, Z., Sun, M., Shen, R., Xue, H. et Fang, F. (2026). **Clinical Spectrum, Heteroplasmy-Phenotype Correlation, and Prognosis of the MT-ND3 m.10191 T > C Mutation.** CNS Neurosci Ther 32, e70997, doi:[10.1002/cns.70997](https://doi.org/10.1002/cns.70997).

Ivanov, Z., Neycheva, I., Halil, Z., Bukov, G., Galabova, F., Ali, S., Kerezov, A., Paskaleva, I. et Yankov, I. (2026). **Cardiac Tamponade After Late Central Venous Catheter Dislodgement in Two Pediatric Patients-A Rare but Potentially Fatal Complication.** Children (Basel) 13, 689, doi:[10.3390/children13050689](https://doi.org/10.3390/children13050689).

Jentsch, L. et Ventura, N. (2026). **Mitochondrial complex I deficiency-associated diseases and models.** Cell Mol Life Sci 83, 249, doi:[10.1007/s00018-026-06169-2](https://doi.org/10.1007/s00018-026-06169-2).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Jerred, C., Ramachandran, H., Hildebrandt, B., Zink, A., Ventura, N., Rossi, A. et Prigione, A. (2026). **Generation of an iPSC line IUFi004-A-13 with homozygous NDUFS1 mutation for the study of Leigh syndrome.** Stem Cell Res 94, 104002, doi:[10.1016/j.scr.2026.104002](https://doi.org/10.1016/j.scr.2026.104002).

Lundquist, A. A., Parikh, S., Hansen, T. van O., Wibrand, F. et Østergaard, E. (2026). **Expanding the MRPS34 Genotype-Phenotype Correlation: Two Novel Cases and a Cohort Review.** JIMD Rep 67, e70089, doi:[10.1002/jmd2.70089](https://doi.org/10.1002/jmd2.70089).

Mekdade, T., Bérat, C.-M., Schiff, M., Gaschignard, M., Bouchereau, J., Arnoux, J.-B., Francoz, C., Servais, A., Dao, M., Lacroix, V., Maquet, J., Imbard, A., Le Guillou, E., Pontoizeau, C., Benoist, J.-F., Oualha, M., Grimaud, M., de Marcellus, C., Sabbah, L., Mayer, C., Chardot, C., Capito, C., Khraiche, D., Lacaille, F., de Lonlay, P. et Brassier, A. (2026). **Long Term Follow-Up After Transplantation in Propionic Acidemia: A Retrospective French Pediatric and Adult Cohort Study.** J Inherit Metab Dis 49, e70216, doi:[10.1002/jimd.70216](https://doi.org/10.1002/jimd.70216).

Menacho, C., Okawa, S., Álvarez-Merz, I., Wittich, A., Muñoz-Oreja, M., Lisowski, P., Martín, M. L., Pentimalli, T. M., Zakin, S., Thevandavakkam, M., Jerred, C., Lickfett, S., Petersilie, L., Rybak-Wolf, A., Seibt, A., Herebian, D., Inak, G., Brodesser, S., Zaliani, A., Mlody, B., Donnelly, J., Woleben, K., Soriano, F. X., Fernandez-Checa, J. C., Ventura, N., Cambridge, S., Mayatepek, E., Spinazzola, A., Schuelke, M., Rajewsky, N., Rossi, A., Peralvarez-Marin, A., Distelmaier, F., Perlstein, E., Holt, I. J., Puighermanal, E., Pless, O., Rose, C. R., Del Sol, A. et Prigione, A. (2026). **Accelerating Leigh syndrome drug discovery through deep learning screening in brain organoids.** Nat Commun 17, 3570, doi:[10.1038/s41467-026-71391-2](https://doi.org/10.1038/s41467-026-71391-2).

Meshrkey, F., Bakare, A. B., Rao, R. R. et Iyer, S. (2026). **Mitochondrial morphology in human fibroblasts and induced pluripotent stem cells in Leigh syndrome: A comparative analysis.** Physiol Rep 14, e70911, doi:[10.14814/phy2.70911](https://doi.org/10.14814/phy2.70911).

Shishimorova, M., Ma, H., Koski, A., Dyken, C. V., Gutierrez, N. M., Frana, D., Li, Y., Eyberg, D., Tevkin, S., Hayama, T., Kang, E., Amato, P., Havlin, K., Goodier, C., Newman, R., Shields, S. et Mitalipov, S. (2026). **Predicting recurrence risk of Leigh syndrome using prenatal mtDNA heteroplasmy assessment.** Mitochondrion 90, 102165, doi:[10.1016/j.mito.2026.102165](https://doi.org/10.1016/j.mito.2026.102165).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Torraco, A., Alston, C. L., Barcia, G., Verrigni, D., Rizza, T., Di Nottia, M., Altobelli, A., Martinelli, D., Diodato, D., Efthymiou, S., Kose, M., Kriouile, Y., Lim, A. Z., Morlino, S., Siri, B., Saadi, N. W., Novelli, A., Houlden, H., Dionisi-Vici, C., McFarland, R., Rötig, A., Bertini, E., Taylor, R. W. et Carrozzo, R. (2026). **Neurological manifestations and genotype-phenotype correlations in NDUFAF6-associated mitochondrial disease.** Brain Commun 8, fcag095, doi:[10.1093/braincomms/fcag095](https://doi.org/10.1093/braincomms/fcag095).

Wang, C., Lin, L., Zhang, Y., Wang, S., Luo, X. et Chen, X. (2026). **Study on Leigh syndrome caused by SURF1 gene mutations and its mechanisms.** Front Neurol 17, 1793054, doi:[10.3389/fneur.2026.1793054](https://doi.org/10.3389/fneur.2026.1793054).

Yang, Q., Zhang, Q., Zhou, X., Qin, Z., Liang, X., Yi, Sheng, Zhang, S., Lu, W., Yi, Shang et Luo, J. (2026). **Clinical and genetic analysis of Chinese patients with Leigh syndrome caused by biallelic loss-of-function variants of the NDUFAF6 gene.** Front Neurol 17, 1778719, doi:[10.3389/fneur.2026.1778719](https://doi.org/10.3389/fneur.2026.1778719).

Maladies mitochondriales (autres) – Mitochondrial disorders (other)

Abady, E., Karam, K. N., Khaleel, S. Q., Kuhn, K., Tamvakologos, P. et Mathew, K. T. (2026). **The invisible emergencies: metabolic and neuro-critical disorders often missed in the pediatric ED - a narrative review.** Int J Emerg Med 19, 79, doi:[10.1186/s12245-026-01186-1](https://doi.org/10.1186/s12245-026-01186-1).

Ahn, A., Hong, S., Brischigliaro, M., Fontanesi, F. et Barrientos, A. (2026). **Folding the message: mRNA structure as a regulatory layer of human mitochondrial gene expression.** Biochim Biophys Acta Mol Cell Res 1873, 120171, doi:[10.1016/j.bbamcr.2026.120171](https://doi.org/10.1016/j.bbamcr.2026.120171).

Ailioaie, C., Ailioaie, L. M., Stan, C. I., Sava, A. et Chiran, D. A. (2026). **Neurodegenerative Diseases in Children: A Comprehensive Review.** Int J Mol Sci 27, 4096, doi:[10.3390/ijms27094096](https://doi.org/10.3390/ijms27094096).

Akinci, G., Sardarzada, J. et Topaloglu, H. (2026). **Transforming the natural course of infantile onset thymidine kinase 2 deficiency through early nucleoside replacement therapy.** J Neuromuscul Dis 22143602261433223, doi:[10.1177/22143602261433223](https://doi.org/10.1177/22143602261433223).

Akyüzlüer Güneş, M. S., Duman, D., Şen, E. K., Yıldırım, M., Özsu, E., Erdeve, Ö., Kaynak Şahap, S., Eminoğlu, F. T. et Köse, E. (2026). **Two Siblings with LRPPRC Mutation: Mitochondrial Complex IV Deficiency: Case Report.** Mol Syndromol 17, 288-295, doi:[10.1159/000548731](https://doi.org/10.1159/000548731).

Al Mutairi, F., Joueidi, F., Al Mutairi, Z. A., Alshalan, M., Eyaid, W., Mushiba, A. M., AlGhamdi, M., Tabarki, B., AlGhamdi, A., AlTassan, R., Alzaidan, H., Sharif, A., Aldhalaan, H., Umair, M. et Alfadhel, M. (2026). **POLG-related disorders: Clinical and molecular**

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Spectrum in the Saudi population. Mol Genet Metab Rep 47, 101322, doi:[10.1016/j.ymgmr.2026.101322](https://doi.org/10.1016/j.ymgmr.2026.101322).

Alghamdi, L. N., Alsudais, A. S., Almarwani, S. H., Alraddadi, R. A., Alsamadani, A. H., Alnamlah, A. A., Aljehani, S. K., Allarakia, Y. F., Alghamdi, A. M. et Alshowaeir, D. (2026). **Gene Therapy for Leber Hereditary Optic Neuropathy (LHON): A Systematic Review and Meta-Analysis.** Neuroophthalmology 50, 215-221, doi:[10.1080/01658107.2026.2624440](https://doi.org/10.1080/01658107.2026.2624440).

Aljawi, A. A. et Badeeb, N. O. (2026). **Leber hereditary optic neuropathy triggered by the AstraZeneca coronavirus disease 2019 vaccination.** Oman J Ophthalmol 19, 137-139, doi:[10.4103/ojo.ojo_431_24](https://doi.org/10.4103/ojo.ojo_431_24).

Aljomah, L., Ertl-Wagner, B. B. et Yeh, E. A. (2026). **Inflammatory or Not: MOG Antibody Positivity and MRI Lesion Resolution in a Mitochondrial Disorder.** Neurology 106, e218054, doi:[10.1212/WNL.0000000000218054](https://doi.org/10.1212/WNL.0000000000218054).

Amaro, T., Bueno, S., Guirão, C., Filho, H. et Scanavacca, M. (2026). **Progressive Conduction Disease in a Mitochondrial Disorder.** JACC Case Rep 107749, doi:[10.1016/j.jaccas.2026.107749](https://doi.org/10.1016/j.jaccas.2026.107749).

Ammar, M., Frikha, F., Chabchoub, I., Alila-Fersi, O., Kharrat, M., Maalej, M., Felhi, R., Tlili, A., Kammoun, T., Mkaouar-Rebai, E. et Fakhfakh, F. (2026). **A novel homozygous MICOS13 frameshift mutation causing mitochondrial hepatoencephalopathy and mtDNA depletion: clinical characterization and dynamic structural simulation.** Mol Biol Rep 53, 666, doi:[10.1007/s11033-026-11839-2](https://doi.org/10.1007/s11033-026-11839-2).

Ando, M., Okamoto, Y., Higuchi, Y., Yuan, J.-H., Yoshimura, A., Yano, C., Nagatomo, R., Hobara, T., Kojima, F., Hiramatsu, Y., Nozuma, S., Sakiyama, Y. et Takashima, H. (2026). **Arginine ameliorates motor and survival deficits in MFN2-Deficient Drosophila models.** Neurotherapeutics 23, e00900, doi:[10.1016/j.neurot.2026.e00900](https://doi.org/10.1016/j.neurot.2026.e00900).

Arena, I. G., Saravanabavan, S., Horvath, R. et van den Amelee, J. (2026). **Non-invasive biomarkers for diagnosis and monitoring of primary mitochondrial diseases.** J Neurol 273, 263, doi:[10.1007/s00415-026-13794-1](https://doi.org/10.1007/s00415-026-13794-1).

Aristizabal-Henao, J. J., Wessel, S. R., Stopka, S. A., Karmacharya, S., Van Cura, D., Pesini, A., Nickerson, K. R., Grover, K., Zavidij, O., Ravi, A., Mota, A. L., Rosen, K. M., Nastke, M.-D., Cox, M. K., Narain, N. R., Modur, V., Quinzii, C. M., Gesta, S. et Kiebish, M. A. (2026). **BPM31510 Increases the CoQ Pool in Chemically Induced CoQ-Deficient Cells, CoQ-Deficient Patient Fibroblasts, and in Metabolically Active Murine Tissues.** FASEB J 40, e71737, doi:[10.1096/fj.202503629RR](https://doi.org/10.1096/fj.202503629RR).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Atlı Şekeroğlu, Z., Şekeroğlu, V., Kamanlı, Ş., Kontaş Yedier, S., Aydın, B. et Börçek Kasurka, C. (2026). **Amelioration of Acrolein-Induced Cytotoxicity, Oxidative Stress, DNA Damage, Apoptosis and Mitochondrial Dysfunction in Human Pancreas Cells by Pycnogenol.** J Biochem Mol Toxicol 40, e70972, doi:[10.1002/jbt.70972](https://doi.org/10.1002/jbt.70972).

Banerjee, R., Purhonen, J., Sultana, N., Ros, O., Nieminen, A. I., Kietz, C., Fellman, V. et Kallijärvi, J. (2026). **Hepatic gene replacement improves energy metabolism and survival in a mouse model of neonatal mitochondrial disease GRACILE syndrome.** Mol Ther S1525-0016(26)00309-6, doi:[10.1016/j.ymthe.2026.04.044](https://doi.org/10.1016/j.ymthe.2026.04.044).

Bangel, K. A., Ng, Y., Lim, A., Thomas, N. J. P., Jaiser, S. R., Lai, H. M., Gorman, G. S., Thomas, R. R., Turnbull, D. M., Ramesh, V., Schaefer, A. M., McFarland, R. et Baker, M. R. (2026). **Adjunctive transcranial DC stimulation in the management of refractory drug-resistant focal epilepsy in POLG mitochondrial disease: A case series.** Seizure S1059-1311(26)00139-1, doi:[10.1016/j.seizure.2026.05.009](https://doi.org/10.1016/j.seizure.2026.05.009).

Basan, H., Kurt, E. E. et Kasapkara, Ç. S. (2026). **An Atypical Neurosensory-Predominant Presentation Associated with a Homozygous NDUFS3 Variant: A Diagnostic Challenge Involving Retinal and Hearing Phenotypes.** Mol Syndromol, doi:[10.1159/000551507](https://doi.org/10.1159/000551507).

Baxter, M. F., Borchert, G. A., Blakely, E. L., Ruan, C. W., MacLaren, R. E., McFarland, R. et Taylor, R. W. (2026). **Ophthalmic manifestations of mitochondrial disorders.** Prog Retin Eye Res 112, 101466, doi:[10.1016/j.preteyeres.2026.101466](https://doi.org/10.1016/j.preteyeres.2026.101466).

Bedoyan, J. K. et Vockley, J. (2026). **Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?** Cell Metab 38, 1079-1080, doi:[10.1016/j.cmet.2026.04.014](https://doi.org/10.1016/j.cmet.2026.04.014).

Bell, S. T., Acín-Pérez, R., Ghouri, I., Meyrick, J., Lightowlers, R. et Russell, O. (2026). **A neuronal model of mtDNA disease reveals an ineffective reprogramming of the electron transfer chain during neuronal maturation.** Mitochondrion 91, 102190, doi:[10.1016/j.mito.2026.102190](https://doi.org/10.1016/j.mito.2026.102190).

Bindi, V., Crespo, C., García, F., Jihye, K., Eiroa, H., Gravina, L. P. et Aráoz, H. V. (2026). **Expanding the Clinical and Genetic Landscape of UQCRC2-related Mitochondrial Complex III Deficiency: A Case Report and Literature Review.** Curr Pediatr Rev, doi:[10.2174/0115733963454034260430145544](https://doi.org/10.2174/0115733963454034260430145544).

Bingol, I., Umur, O., Sık, S. G., Yilmaz, T. U., Emiroglu, R. et Citak, A. (2026). **Acute Liver Failure following Valproate Exposure in a Teenager with Homozygous POLG c.2243G>C (p.Trp748Ser) Mutation: Late-Onset Presentation and Successful Liver Transplantation - A Case Report.** Mol Syndromol, doi:[10.1159/000552241](https://doi.org/10.1159/000552241).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Blackbourn, L. W., Chandrasekar, K. K., Peddireddy, N. et Blume, G. M. (2026). **A Diagnostic Conundrum: Atypical McArdle Disease Mimic With Heterozygous PYGM Mutation and Cytochrome C Oxidase (COX)-Negative Fibers.** *Cureus* 18, e109817, doi:[10.7759/cureus.109817](https://doi.org/10.7759/cureus.109817).

Boschann, F., Kopp, J., Römer, S., Küchler, O., Lyubenova, H., von Kügelgen, N., Hertstein, E., Hagelstein, L., Becker, C., Becker, K., Brachs, S., Mai, K., Meierhofer, D., Seelow, D., Mundlos, S., Horn, D., Schuelke, M. et Fischer-Zirnsak, B. (2026). **A biallelic MRPL42 variant causes a combined oxidative phosphorylation deficiency syndrome revealed by multi-omics.** *NPJ Genom Med* 11, 20, doi:[10.1038/s41525-026-00564-1](https://doi.org/10.1038/s41525-026-00564-1).

Brooks, D. R., Koh, H. Y., Kerrins, T. M., Lang, S., Bland, E., Yang, R., Nicholas, S. K., Sikkink, S. J., Kralik, S., Eng, C., Murali, C. N., Lalani, S., Magoulas, P. L., Emrick, L., Fisher, K. S. et Scaglia, F. (2026). **JAK Inhibition in PNPT1-Related Mitochondrial Interferonopathy: A Case Report and Review of Mitochondrial-Immune Crosstalk.** *JIMD Rep* 67, e70096, doi:[10.1002/jmd2.70096](https://doi.org/10.1002/jmd2.70096).

Capela, J., Reis, M., Almeida, I., Novo, M., Ramalho, A., Lipari, P. et Rodrigues, M. (2026). **A Novel Combination of Biallelic Variants in the VARS2 Gene: A Severe Phenotype.** *Acta Med Port*, doi:[10.20344/amp.23831](https://doi.org/10.20344/amp.23831).

Carroll-Deaton, J. A., Bohovych, I., Emetu, F. T., Dietz, J. V., Rivett, E. D., Stanley, E., Hegg, E. L., Fox, J. L. et Khalimonchuk, O. (2026). **Molecular analysis of a new patient COX15 mutation provides insight into the etiology of fatal infantile cardioencephalopathy.** *J Biol Chem* 302, 111475, doi:[10.1016/j.jbc.2026.111475](https://doi.org/10.1016/j.jbc.2026.111475).

Chandrasegaram, R., Gottardo, S., Dhawanjewar, A., Hynes-Allen, A. M., Gao, B., Chowdhury, S. R., Tábara, L.-C., Frison, M., Petridi, S., Chinnery, P. F., Prudent, J., Ma, H. et van den Amele, J. (2026). **Single-molecule mitochondrial DNA imaging reveals heteroplasmy dynamics shaped by developmental bottlenecks and selection in vivo.** *Dev Cell* 61, 1146-1161.e8, doi:[10.1016/j.devcel.2026.03.011](https://doi.org/10.1016/j.devcel.2026.03.011).

Chen, W., Wang, X., Liu, P., Kang, Y., Hayashi, T., Mizuno, K., Hattori, S., Fujisaki, H., Liu, W. et Ikejima, T. (2026). **Silibinin restricts mitochondria-associated inflammatory pathways in LPS-stimulated murine microglia BV2 through TREM2.** *Cell Immunol* 425, 105102, doi:[10.1016/j.cellimm.2026.105102](https://doi.org/10.1016/j.cellimm.2026.105102).

Cheung, A. C. T., Berrahmoune, S., Dassi, C., Pেকেles, H., Gagnon, T., Waters, P. J., Eberhard, R., Buhas, D. et Myers, K. A. (2026). **Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.** *Neurotherapeutics* 23, e00945, doi:[10.1016/j.neurot.2026.e00945](https://doi.org/10.1016/j.neurot.2026.e00945).

Chico, L., Lopriore, P., Cecchi, G., Meli, A., Bernardini, C., Balestrini, L., Polzella, M., Montano, V. et Mancuso, M. (2026). **Evaluating a Coenzyme Q10-Based Food for Special Medical Purpose, for Mitochondrial Diseases Management: An Open-Label, Pilot Trial.** *Int J Mol Sci* 27, 5127, doi:[10.3390/ijms27115127](https://doi.org/10.3390/ijms27115127).



Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Cicala, G., Rolleri, E., Berti, B., Luigetti, M., Forcina, N., Villa, M., Capasso, A., Arpaia, C., Malaspina, M., Fattori, F., Bosco, L., Primiano, G., Novelli, A., Rizza, T., Bertini, E., Pane, M. et Mercuri, E. (2026). **Compound Heterozygous COA7 Variants Presenting With Childhood-Onset Axonal Neuropathy in 2 Siblings.** *Neurol Genet* 12, e200394, doi:[10.1212/NXG.0000000000200394](https://doi.org/10.1212/NXG.0000000000200394).

Coelho, P., Dionísio, P., A Sardão, V., Dias, R. A., Futschik, M. E., Klemm, R., Milosevic, I. et Raimundo, N. (2026). **Mitochondrial dysfunction triggers a maladaptive peroxisomal response driving lipid accumulation.** *Redox Biol* 93, 104166, doi:[10.1016/j.redox.2026.104166](https://doi.org/10.1016/j.redox.2026.104166).

Cornejo, M. C., Lee, S. C.-E. S., Smith, S. et Koehler, C. M. (2026). **Consequences of defective mitochondrial protein import: From targeting signals to pathology.** *Biochim Biophys Acta Biomembr* 184546, doi:[10.1016/j.bbamem.2026.184546](https://doi.org/10.1016/j.bbamem.2026.184546).

Corrà, S., Balmaceda, V. et Viscomi, C. (2026a). **Adeno-Associated virus-based approaches for mitochondrial diseases: advances and challenges.** *Mol Psychiatry*, doi:[10.1038/s41380-026-03570-y](https://doi.org/10.1038/s41380-026-03570-y).

Corrà, S., Young, L., Moore, A. L. et Viscomi, C. (2026b). **Mitochondrial disease: mechanisms, signalling, and therapeutic opportunities.** *Free Radic Biol Med* 253, 749-769, doi:[10.1016/j.freeradbiomed.2026.06.013](https://doi.org/10.1016/j.freeradbiomed.2026.06.013).

D'Alessio, A. M., Indrieri, A., Vitiello, G., Morleo, M., Schelley, S., Enns, G. M., Passarelli, C., Tammaro, R., Tiranti, V., Peron, C., Deb, W., Novelli, A., Isidor, B., Iolascon, A. et Franco, B. (2026). **Revisiting LSDMCA: male lethality escape and genotype-phenotype correlations.** *Eur J Hum Genet*, doi:[10.1038/s41431-026-02098-7](https://doi.org/10.1038/s41431-026-02098-7).

de Schotten, M. T., Liu, C. C., Kelly, C., Bo, K., Wager, T. D., Mosharov, E. V. et Picard, M. (2026). *Individualised mapping of living human brain mitochondria by MRI reveals signatures of bioenergetic defects*, doi:[10.64898/2026.06.09.730804](https://doi.org/10.64898/2026.06.09.730804).

Dhillon, H. K. et Raghu, N. (2026). **Strabismus as a primary presentation of combined OXPHOS deficiency: a case of GTPBP3 mutations.** *Strabismus* 34, 234-237, doi:[10.1080/09273972.2025.2571777](https://doi.org/10.1080/09273972.2025.2571777).

Dietz, C. D., Deniz, K., Fong, J. C., Cha, S., Rankin, K. P., Lee, S. E., Geschwind, M. D. et Windon, C. C. (2026). **A single large-scale mitochondrial DNA deletion presenting as rapidly progressive dementia in a 35-year-old male.** *NPJ Dement* 2, 25, doi:[10.1038/s44400-026-00081-z](https://doi.org/10.1038/s44400-026-00081-z).

DiFalco, C. R., Williams, A., Soler-Alfonso, C., Waskow, E., Mizerik, E., Scaglia, F. et Murali, C. N. (2026). **A Case of Multiple Mitochondrial Dysfunctions Syndrome 1 and Review of the Literature.** *Am J Med Genet A*, doi:[10.1002/ajmg.a.70213](https://doi.org/10.1002/ajmg.a.70213).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Domínguez-González, C., Garone, C., Nascimento, A., Ma, Y., Boudiaf, N., Kim, R., VanMeter, S., Brunnert, M. et Hirano, M. (2026). **Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient dataset.** Brain Commun 8, fcag200, doi:[10.1093/braincomms/fcag200](https://doi.org/10.1093/braincomms/fcag200).

Dupic, A., Evangelista, T., Labella, B., Gaignard, P., Becker, P. H., Turmel, H., Konyukh, M. et Masingue, M. (2026). **A COA8 homozygous mutation presenting as an intermediate CMT with leukopathy.** Neuromuscul Disord 64, 106442, doi:[10.1016/j.nmd.2026.106442](https://doi.org/10.1016/j.nmd.2026.106442).

Esnaola, G. R. et Goetzl, E. J. (2026). **New understanding and treatment of adult mitochondrial dysfunction: an example of personalized precision medicine.** Am J Med S0002-9343(26)00288-3, doi:[10.1016/j.amjmed.2026.04.018](https://doi.org/10.1016/j.amjmed.2026.04.018).

Falabella, M., Lopez Calcerrada, S., Aref, J., Gao, J., Macken, W. L., Pizzamiglio, C., Kabiljo, R., Francavilla, A. L., Gaignard, P., Pouzet, A., Levy, J., Barcia, G., Leighton, J. K., Chronopoulou, E., Pierre, G., Köksal Özgül, R., Dursun, A., Halligan, R., Mundy, H., Raza Alvi, J., Sultan, T., Craigen, W. J., Emrick, L., Rosenfeld, J. A., Elmakkawy, G., Kim, J., Gleeson, J. J., Rad, A., Oprea, G., Hussain, M., Rehman, K. U., Riaz, S., Taylor, R. W., Procaccio, V., Zaki, M. S., Fernandez-Vizarra, E., Pierri, C. L., Hanna, M. G., Houlden, H., Maroofian, R., Ugalde, C., Taanman, J.-W. et Pitceathly, R. D. S. (2026). **COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy.** Nat Commun, doi:[10.1038/s41467-026-73455-9](https://doi.org/10.1038/s41467-026-73455-9).

Fernández-Del-Río, L., Eastes, A., Pacheco, D. R. F., Scillitani, N., Garza, J., Dugan, M., de Oliveira, M. P., Kadam, P., Gauhar, I., Erion, K., Rodgers, K., Gaffney, K., Wang, A., Liesa, M., Benincá, C. et Shirihai, O. S. (2026). **Activation of the protective arm of renin-angiotensin system enhances mitochondrial turnover improving respiration and decreasing integrated stress response in a human Complex III deficiency model.** doi:[10.64898/2026.03.20.711686](https://doi.org/10.64898/2026.03.20.711686).

Ferrera, G., Boenzi, S., Lamantea, E., Ghezzi, D. et Ardisson, A. (2026). **β-ureidopropionase deficiency mimicking Leigh syndrome associated with methylmalonic aciduria.** BMJ Case Rep 19, e272561, doi:[10.1136/bcr-2026-272561](https://doi.org/10.1136/bcr-2026-272561).

Finsterer, J. (2026a). **Before a spinal cord lesion in an m.3243A>G carrier is attributed to mitochondrial disease, all differential diagnoses must be excluded.** Rinsho Shinkeigaku 66, 420-421, doi:[10.5692/clinicalneuro.002190](https://doi.org/10.5692/clinicalneuro.002190).

Finsterer, J. (2026b). **Commentary: Profiles of paediatric patients experiencing stroke-like episodes associated with mitochondrial disease.** Front Neurol 17, 1775667, doi:[10.3389/fneur.2026.1775667](https://doi.org/10.3389/fneur.2026.1775667).

Finsterer, J. (2026c). **Gastrointestinal Pseudo-Obstruction Is Not an Uncommon Phenotypic Manifestation of POLG1 Variants.** Eur J Neurol 33, e70655, doi:[10.1111/ene.70655](https://doi.org/10.1111/ene.70655).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Finsterer, J. (2026d). **New-born Screening for Mitochondrial Disorders is Useful for Genetic Counseling and Early Treatment when Available.** J Obstet Gynaecol India 76, 276-277, doi:[10.1007/s13224-024-02075-4](https://doi.org/10.1007/s13224-024-02075-4).

Finsterer, J. (2026e). **Perrault Plus Syndrome Due to the LARS2 Variant c.457A>C Manifesting With Epilepsy, Cognitive Impairment, Myopathy, Spastic Tetraparesis, and Deafness: A Case Report.** Cureus 18, e106193, doi:[10.7759/cureus.106193](https://doi.org/10.7759/cureus.106193).

Glasgow, R. I. C., Lennartsson, F., Arnardottir, S., Shiriaev, D. I., Correia, S. P., Moedas, M., Peña-Pérez, L., Paucar, M., Naess, K., Bruhn, H., Lesko, N., Wibom, R., Rorbach, J., Freyer, C., Wedell, A., Ygberg, S., Eklund, E. A. et Wredenberg, A. (2026). **MRPS22 variants alter mitochondrial ribosome assembly in patients with leukodystrophy, movement disorder and intellectual impairment.** Hum Mol Genet 35, ddag042, doi:[10.1093/hmg/ddag042](https://doi.org/10.1093/hmg/ddag042).

Gök, A., Cırdı, G., Deniz, A., Sakarya Güneş, A., Tekin Orgun, L. et Kara, B. (2026). **Leber hereditary optic neuropathy (LHON) in a 6-year-old boy with a transient spinal cord lesion.** Turk J Pediatr 68, 330-336, doi:[10.24953/turkpediatr.2026.6882](https://doi.org/10.24953/turkpediatr.2026.6882).

Gonzalez-Carranza, H. R. et Reyes-Vallejo, L. A. (2026). **Paradoxical hypolibido in a hyperandrogenic male with POLG-related mitochondrial disease.** J Sex Med 23, qdag187, doi:[10.1093/jsxmed/qdag187](https://doi.org/10.1093/jsxmed/qdag187).

Grynblat, J., Eyries, M., Ambar-Akkaoui, M., Levy, M., Meot, M., Szezepanski, I., Ranchoup, J., Callegari, A., Karila-Cohen, J., Bonnet, C., Marijon, P., Champ, J., Coulet, F., Ovaert, C., Perros, F., Antigny, F., Maragnes, P., Vaksman, G., Humbert, M., Malekzadeh Milani, S. G., Montani, D. et Bonnet, D. (2026). **The preponderance of genetic variations in paediatric pulmonary hypertension.** Respir Med Res 89, 101277, doi:[10.1016/j.resmer.2026.101277](https://doi.org/10.1016/j.resmer.2026.101277).

Guo, R. et Yang, M. (2026). **Mammalian Respiratory Chain Complex Assemblies and Their Links to Mitochondria Stress-Induced Human Diseases.** Adv Exp Med Biol 1514, 299-330, doi:[10.1007/978-3-032-26629-3_11](https://doi.org/10.1007/978-3-032-26629-3_11).

Han, Y., Chen, N., Song, P., Chen, Y. et Tang, W. (2026). **Stem cell-derived extracellular vesicles for rare diseases: A clinical-bottleneck-to-mechanism framework for translation.** Biosci Trends, doi:[10.5582/bst.2026.01150](https://doi.org/10.5582/bst.2026.01150).

Hanaford, A. R., Olkhova, E. A., Liao, R., Ching, A., Huang, A., Hsieh, E. S., Watanabe, K., Chen, Y., Wichman, M., Hwang, N., James, K., Mulholland, M., Truong, V., Coulson, H., Gibbins, K., Cairns, O., Dimitriou, A., Kayser, B., Johnson, B. M., Sarkar, S., Kalia, V. et Johnson, S. C. (2026). **MyD88 deficiency modestly attenuates disease in a Leigh syndrome mouse model while enrofloxacin accelerates disease.** doi:[10.64898/2026.05.13.724988](https://doi.org/10.64898/2026.05.13.724988).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Haschke, A. M., von Renesse, A., Graceffo, E., Morales-Gonzalez, S., Prigione, A., Hübner, C., Stenzel, W. et Schuelke, M. (2026). **Biallelic MCUR1 nonsense mutation associated with vacuolar myopathy and altered mitochondrial calcium signaling.** Acta Neuropathol Commun 14, 107, doi:[10.1186/s40478-026-02313-y](https://doi.org/10.1186/s40478-026-02313-y).

Hathazi, D., Lyons, C., Lagos, D., Podmanicky, O., Zarate-Mendez, M., Nie, Y., Müller, J. S., Allinson, K. S. J., Naylor, H., Lako, M., Elsharkawi, I., Muffels, I., Morava, E., Kozicz, T., Chinnery, P., Lakatos, A. et Horvath, R. (2026). **Mitochondrial DNA heteroplasmy drives cortical neuronal disturbances in human organoids harbouring the common m.3243A>G mutation.** Nat Commun, doi:[10.1038/s41467-026-74103-y](https://doi.org/10.1038/s41467-026-74103-y).

Hernández-Cruz, E. Y. et Uribe-Carvajal, S. (2026). **The Caenorhabditis elegans mitochondrial electron transport chain: its role in adaptation, longevity, and biotechnology.** Exp Cell Res 459, 115026, doi:[10.1016/j.yexcr.2026.115026](https://doi.org/10.1016/j.yexcr.2026.115026).

Hirano, M., Garone, C., Haas, R., Paradas, C., Scaglia, F., Rebollo Mesa, I., Chiang, C., Colson, A.-O., VanMeter, S. et Domínguez-González, C. (2026). **Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency.** Brain Commun 8, fcag201, doi:[10.1093/braincomms/fcag201](https://doi.org/10.1093/braincomms/fcag201).

Horibata, Y., Sato, T., Ohyama, M., Yuyama, S., Itoh, M., Miura, S., Konishi, A. et Sugimoto, H. (2026). **Loss of STARD7 Impairs Mitochondrial Phospholipid Homeostasis and Contributes to Mitochondrial Myopathy.** FASEB J 40, e71777, doi:[10.1096/fj.202504528R](https://doi.org/10.1096/fj.202504528R).

Hoytema van Konijnenburg, E. M. M., Ying, J., Salomons, G. S., Wortmann, S. B., Muffels, I. J. J. et Fuchs, S. A. (2026). **Mitochondrial aminoacyl-tRNA synthetase (ARS)-defects: a review of phenotypes and therapeutic strategies in 899 patients.** Genet Med 102608, doi:[10.1016/j.gim.2026.102608](https://doi.org/10.1016/j.gim.2026.102608).

Hu, J., Liufu, T., Li, C., Zhao, Q., Yu, M., Yuan, Y., Quan, L., Chen, Z. et Wang, Z. (2026). **Detection of NADH/NAD⁺ dysregulation in MELAS via diazo-carboxyl click derivatization mass spectrometry.** Clin Chim Acta 591, 121172, doi:[10.1016/j.cca.2026.121172](https://doi.org/10.1016/j.cca.2026.121172).

Huang, K., Huang, Y., Zhang, Yuhuan, Zhang, Yixuan, Hatch, N. W., Freed, J. K. et Cai, H. (2026). **Endothelial NOX1 Drives Obesity via Skeletal Muscle Mitochondrial Dysfunction.** Circ Res 138, e326768, doi:[10.1161/CIRCRESAHA.125.326768](https://doi.org/10.1161/CIRCRESAHA.125.326768).

Jacob, P., Deepa, S., Hassan, A. V., Rao, S., Santhoshkumar, R., Vasudeva, K., Kapahtia, S., Sharma, M., Nandeesh, B. N., Nagappa, M. et Govindaraj, P. (2026). **TTC19 and FMNL2 gene variants in a pediatric case of mitochondrial disorder with renal tubular acidosis.** Mitochondrion 91, 102183, doi:[10.1016/j.mito.2026.102183](https://doi.org/10.1016/j.mito.2026.102183).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Jadhav, T., Aruta, M., Diaz-Miranda, M. A., Zucco, A., Conlin, L. K., Rajagopalan, R. et Wang, J. (2026). **Evaluation of PacBio Long-Read and PCR-Based Short-Read Sequencing for Mitochondrial DNA (mtDNA) Variant Detection, with an Emphasis on Detection and Quantification of mtDNA Deletion.** Int J Mol Sci 27, 3562, doi:[10.3390/ijms27083562](https://doi.org/10.3390/ijms27083562).

Jentsch, L. et Ventura, N. (2026). **Mitochondrial complex I deficiency-associated diseases and models.** Cell Mol Life Sci 83, 249, doi:[10.1007/s00018-026-06169-2](https://doi.org/10.1007/s00018-026-06169-2).

Jerred, C., Ramachandran, H., Hildebrandt, B., Zink, A., Ventura, N., Rossi, A. et Prigione, A. (2026). **Generation of an iPSC line IUFi004-A-13 with homozygous NDUF51 mutation for the study of Leigh syndrome.** Stem Cell Res 94, 104002, doi:[10.1016/j.scr.2026.104002](https://doi.org/10.1016/j.scr.2026.104002).

Jiang, Q., Duan, J., Liu, C., Zhu, Y., Zeng, Q., Hu, Y., Luo, Z., Cao, D., Liao, J. et Chen, L. (2026). **Beyond the genome: clinical challenges in diagnosing LONP1-related mitochondrial disorders.** Front Cell Dev Biol 14, 1779332, doi:[10.3389/fcell.2026.1779332](https://doi.org/10.3389/fcell.2026.1779332).

Jimenez-Moreno, A. C., Blain, A., Pinto, C. A., Soekhai, V., Johansson, J. V., Dyer, C., Adcock, K., de Bekker-Grob, E. W., de Wit, G. A., Newman, J. et Gorman, G. S. (2026). **Patient Preferences in Neuromuscular Diseases: Insights for Future Drug Development.** JIMD Rep 67, e70100, doi:[10.1002/jmd2.70100](https://doi.org/10.1002/jmd2.70100).

Jones, A., Zelenková, N., Mantle, E., Gardner, C., Klusáčková, B., Zuidema, D., Sutovsky, M., Postlerová, P., Zigo, M. et Sutovsky, P. (2026). **Phenotyping of post-fertilization sperm mitophagy determinants discovered in a mammalian gamete-based cell-free system.** Biol Res, doi:[10.1186/s40659-026-00713-x](https://doi.org/10.1186/s40659-026-00713-x).

Kafetzopoulos, G., Döbler, J. et Kastiris, P. L. (2026). **Higher-order structural organization of mitochondrial metabolism.** J Biol Chem 302, 113174, doi:[10.1016/j.jbc.2026.113174](https://doi.org/10.1016/j.jbc.2026.113174).

Khan, G. S., Bayat, S., Azizimalamiri, R., Nikoohemmat, M., Mashayekhi, N., Nabilou, S., Tavasoli, A. R., Ashrafi, M. R. et Heidari, M. (2026). **Expanding the Clinical Spectrum of LYRM7-Associated Mitochondrial Complex III Deficiency: Insights from New Cases and Literature Review.** J Mol Neurosci 76, 72, doi:[10.1007/s12031-026-02527-8](https://doi.org/10.1007/s12031-026-02527-8).

Khan, N. A. et Torregrosa-Muñumer, R. (2026). **Editorial: Beyond energy production: exploring mitochondrial dynamics and disease.** Front Cell Dev Biol 14, 1872916, doi:[10.3389/fcell.2026.1872916](https://doi.org/10.3389/fcell.2026.1872916).

Khattar, S., Rizk, P. et Tleiss, F. (2026). **Fatal Infantile Hepatic Dysfunction Associated With TRMU Gene Mutation and Aggravated by Cytomegalovirus Infection: A Unique Case.** Cureus 18, e104646, doi:[10.7759/cureus.104646](https://doi.org/10.7759/cureus.104646).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Khodawrdi, A., Mekki, C., Lunati-Rozie, A. et Funalot, B. (2026). **Adult case of 17 β -hydroxysteroid dehydrogenase type 10 (HSD10) deficiency due to the p. Arg130Cys mutation of the HSD17B10 gene: case report.** AME Case Rep 10, 68, doi:[10.21037/acr-24-280](https://doi.org/10.21037/acr-24-280).

Kneebone, E., Russell, Z., Newson, A. J., Degeling, C., Ludlow, K., Warren, N. et Mills, C. (2026). **Public support for mitochondrial donation: an Australian knowledge and attitudes study.** Reprod Biomed Online 52, 105464, doi:[10.1016/j.rbmo.2026.105464](https://doi.org/10.1016/j.rbmo.2026.105464).

Kong, L., Liang, J., Liu, D., Jia, S., Gu, H., He, Y., Luo, W., Cao, S., Dong, Y., Yang, C., Liao, M., Wan, G., Du, B., Ding, D., Ma, W., Wei, X., Wu, A. et Yuan, Z. (2026). **Intra-mitochondrial glycolysis maintains mitochondrial function and underlies the pathogenesis of retinitis pigmentosa.** Nat Commun, doi:[10.1038/s41467-026-72988-3](https://doi.org/10.1038/s41467-026-72988-3).

Lan, S.-C., Chang, Y.-Y., Chen, S.-F., Chen, Y.-F. et Lan, M.-Y. (2026). **Mitochondrial complex III deficiency nuclear type 2: a case report and analysis of clinical onset age-related phenotypic features.** Neurol Sci 47, 475, doi:[10.1007/s10072-026-09073-6](https://doi.org/10.1007/s10072-026-09073-6).

Lapshin, E. V., Egorov, A. D., Malogolovkin, A. S., Gasanov, N. B., Smirnikhina, S. A., Tabakov, V. Y. et Karabelsky, A. V. (2026). **Optimized ND4 allotopic expression for gene therapy of Leber's hereditary optic neuropathy.** Front Bioeng Biotechnol 14, 1765995, doi:[10.3389/fbioe.2026.1765995](https://doi.org/10.3389/fbioe.2026.1765995).

Lee, T., Matsui, M., Yokoyama, Y., Bo, R., Awano, H., Kataoka, D., Ueda, M., Minato, T., Kobayashi, H., Hasegawa, Y., Murayama, K. et Takeshima, Y. (2026). **A Four-Year Prospective Pilot Study of Newborn Screening for Late-Onset Proximal Urea-Cycle Disorders in Hyogo Prefecture in Japan.** Int J Neonatal Screen 12, 39, doi:[10.3390/ijns12020039](https://doi.org/10.3390/ijns12020039).

Li, H. et Micieli, J. (2026). **Leber Hereditary Optic Neuropathy in the Elderly: A Case Report.** Case Rep Ophthalmol 17, 305-311, doi:[10.1159/000551146](https://doi.org/10.1159/000551146).

Li, M., Sasai, H., Taniguchi, H., Ishida, A., Kuwabara, Y., Matsumoto, H., Terazawa, D., Kanayama, T., Miyazaki, T., Hara, A. et Murayama, K. (2026). **DGUOK-related mitochondrial DNA depletion syndrome presenting with neonatal cholestasis without marked hyperlactatemia: A diagnostic pitfall.** Mol Genet Metab Rep 47, 101314, doi:[10.1016/j.ymgmr.2026.101314](https://doi.org/10.1016/j.ymgmr.2026.101314).

Li, P., Li, L., Guo, M., Xu, J. et Cai, Y. (2026). **DDRGK1 regulates muscle development by maintaining mitochondrial calcium homeostasis and oxidative phosphorylation via stabilizing IP3R.** Mol Biol Rep 53, 817, doi:[10.1007/s11033-026-12009-0](https://doi.org/10.1007/s11033-026-12009-0).

Li, S., Li, Y. et Chen, Y. (2026). **Mitochondrial encephalomyopathy caused by a novel ACAD9 mutation: a case report.** Front Hum Neurosci 20, 1828023, doi:[10.3389/fnhum.2026.1828023](https://doi.org/10.3389/fnhum.2026.1828023).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Li, Y., Han, S., Huang, D., Chen, J., Qu, S., Gu, J., Xu, Z., Fu, L., Tang, X. et Qiao, Y. (2026). **Mitochondrial mutation status, symptom prevalence, and neuroimaging characteristics in MELAS: a systematic review and meta analysis.** Orphanet J Rare Dis, doi:[10.1186/s13023-026-04448-6](https://doi.org/10.1186/s13023-026-04448-6).

Liu, Y., Wang, N. et Cai, H. (2026). **Curcumin Protects SDH2 Mutant from Oxidative Stress and Improves Mitochondrial Function: Application Potential for Complex II Deficiency.** Int J Mol Sci 27, 5253, doi:[10.3390/ijms27125253](https://doi.org/10.3390/ijms27125253).

Liu, Z., Duan, X., Peymani, F., Wang, Jia, Bao, C., Xu, C., Zou, Y., Zhang, Z., Zhang, Y., Li, T., Pavlov, M., Wang, Junling, Song, M., Song, T., Han, X., Sun, M., Shen, D., Duan, R., Jiang, H., Xu, M., Prokisch, H. et Fang, F. (2026). **RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease.** Ann Clin Transl Neurol, doi:[10.1002/acn3.70379](https://doi.org/10.1002/acn3.70379).

Lundquist, A. A., Parikh, S., Hansen, T. van O., Wibrand, F. et Østergaard, E. (2026). **Expanding the MRPS34 Genotype-Phenotype Correlation: Two Novel Cases and a Cohort Review.** JIMD Rep 67, e70089, doi:[10.1002/jmd2.70089](https://doi.org/10.1002/jmd2.70089).

Luo, X., Li, L. et Su, G. (2026). **Case Report: A young man with mitochondrial disease: intellectual impairment and myocardial hypertrophy.** Front Cardiovasc Med 13, 1802202, doi:[10.3389/fcvm.2026.1802202](https://doi.org/10.3389/fcvm.2026.1802202).

Madsen, S., Allender, B., Blackford, R., Bollard, T., Comerford, A., Johnson, M. L., Sinha, R., Vanatta, L., Whiteley, V. J., Schoeler, N. E., et Ketogenic Dietitians Research Network (2026). **Ketogenic diet therapy in pyruvate dehydrogenase deficiency: Global clinical practice from literature and survey data.** Mol Genet Metab 148, 110190, doi:[10.1016/j.ymgme.2026.110190](https://doi.org/10.1016/j.ymgme.2026.110190).

Mancuso, M., Bellusci, M., Carelli, V., de Co, I., Diodato, D., Distelmaier, F., Hikmat, O., Hirano, M., Horvath, R., Karaa, A., Klopstock, T., Koenig, M. K., Kornblum, C., La Morgia, C., Lopriore, P., Martikainen, M. H., McFarland, R., Musumeci, O., Pitceathly, R. D. S., Primiano, G., Rahman, S., Scaglia, F., Schaefer, A., Schiff, M., Semmler, L., Lamperti, C. et Servadei, S. (2026). **Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements.** Eur J Neurol 33, e70588, doi:[10.1111/ene.70588](https://doi.org/10.1111/ene.70588).

Mantecon, M., Chhuon, C., Roger, K., Guerrera, I. C., Bole, C., Nitschke, P., Dufeu-Bérat, C.-M., Ashcroft, M., Taylor, R. W., Boddaert, N. et Rötig, A. (2026). **Biallelic variants in CHCHD4 are associated with combined OXPHOS defect leading to mitochondrial disease.** HGG Adv 7, 100615, doi:[10.1016/j.xhgg.2026.100615](https://doi.org/10.1016/j.xhgg.2026.100615).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Marcuzzo, M. B., Zemniçak, Â. B., da Rosa, J. S., Verdi, B. S. S., Benati, M. P. D. V., de Andrade Silveira, J., do Nascimento, J. G., de Almeida Moreira, H., Dias-Oliveira, M., Souza, D. O., Amaral, A. U., Zanatta, G., Wajner, M. et Leipnitz, G. (2026). **Ethylmalonic and Methylsuccinic Acids Disrupt Bioenergetics and Induce Mitochondrial Permeability Transition Through Thiol Redox Modulation in Rat Striatum: Potential Mechanisms Involved in Ethylmalonic Encephalopathy.** *Neurochem Res* 51, 176, doi:[10.1007/s11064-026-04801-y](https://doi.org/10.1007/s11064-026-04801-y).

Martin, I., Flickinger, J., Rahaman, I., Sarna, T., Ballance, E. B., Ginelli, N., Peterson, J. T., Uryash, A., Adams, J. A., Xiao, R. et Zolkipli-Cunningham, Z. (2026). **Quantitative assessment of efficacy and evaluation of feasibility of exercise training protocols in adult and pediatric primary mitochondrial disease.** *BMC Med*, doi:[10.1186/s12916-026-04944-3](https://doi.org/10.1186/s12916-026-04944-3).

Mehri, S. et Finsterer, J. (2026). **Recurrent Miscarriages and Postpartum Heart Failure Can Be Phenotypic Manifestations of the m.3243A>G Variant.** *Clin Case Rep* 14, e72935, doi:[10.1002/ccr3.72935](https://doi.org/10.1002/ccr3.72935).

Menacho, C., Okawa, S., Álvarez-Merz, I., Wittich, A., Muñoz-Oreja, M., Lisowski, P., Martín, M. L., Pentimalli, T. M., Zakin, S., Thevandavakkam, M., Jerred, C., Lickfett, S., Petersilie, L., Rybak-Wolf, A., Seibt, A., Herebian, D., Inak, G., Brodesser, S., Zaliani, A., Mlody, B., Donnelly, J., Woleben, K., Soriano, F. X., Fernandez-Checa, J. C., Ventura, N., Cambridge, S., Mayatepek, E., Spinazzola, A., Schuelke, M., Rajewsky, N., Rossi, A., Peralvarez-Marin, A., Distelmaier, F., Perlstein, E., Holt, I. J., Puighermanal, E., Pless, O., Rose, C. R., Del Sol, A. et Prigione, A. (2026). **Accelerating Leigh syndrome drug discovery through deep learning screening in brain organoids.** *Nat Commun* 17, 3570, doi:[10.1038/s41467-026-71391-2](https://doi.org/10.1038/s41467-026-71391-2).

Meshrkey, F., Bakare, A. B., Rao, R. R. et Iyer, S. (2026). **Mitochondrial morphology in human fibroblasts and induced pluripotent stem cells in Leigh syndrome: A comparative analysis.** *Physiol Rep* 14, e70911, doi:[10.14814/phy2.70911](https://doi.org/10.14814/phy2.70911).

Mickelsson, N., Hirvonen, J. et Martikainen, M. H. (2026). **Progressive White Matter Changes in Mitochondrial Disease: A Quantitative MRI Study.** *JIMD Rep* 67, e70093, doi:[10.1002/jmd2.70093](https://doi.org/10.1002/jmd2.70093).

Mitra, K., Kim, S., Oettinger, D., Uthishtran, S., Zhao, Q., Veetil, A. T., Ramirez, J. R., Lin, H., Arumugam, S. et Krishnan, Y. (2026). **A ratiometric fluorescent reporter of mitochondrial sodium.** *Nat Chem Biol*, doi:[10.1038/s41589-026-02253-7](https://doi.org/10.1038/s41589-026-02253-7).

Mohsen, M., Juma, S., Saleh, D., Saleh, T., Amayra, A. et Atrash, J. (2026). **From confusion to diagnosis: a rare case of melas syndrome in a patient with familial consanguinity, recurrent stroke-like episodes, and concurrent FSGS.** *BMC Neurol* 26, 317, doi:[10.1186/s12883-026-04853-1](https://doi.org/10.1186/s12883-026-04853-1).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Molina-Berenguer, M., Herrero-Martínez, D., Vallbona-Garcia, A., Vila-Julià, F., Cámara, Y., Vales, Á., González-Aseguinolaza, G., Torres-Torronteras, J. et Martí, R. (2026). **Systemic delivery of AAV-GFM1 corrects COXPD1 molecular alterations in Gfm1R671C/- mice.** EMBO Mol Med 18, 2152-2179, doi:[10.1038/s44321-026-00426-4](https://doi.org/10.1038/s44321-026-00426-4).

Moos, W. H., Faller, D. V., Glavas, I. P., Kanara, I., Kodukula, K., Pernokas, J., Pernokas, M., Pinkert, C. A., Powers, W. R., Sampani, K., Steliou, K. et Vavvas, D. G. (2026). **Mitoredox shifts in mitochondrial dysfunction.** Free Radic Biol Med 253, 131-147, doi:[10.1016/j.freeradbiomed.2026.05.307](https://doi.org/10.1016/j.freeradbiomed.2026.05.307).

Norden, P. R., Wedan, R. J., Ellis, A. E., Hart, M. L., Gendjar, M. R., Sheldon, R. D. et Nowinski, S. M. (2026). *Functional partitioning of lipoic acid decouples cellular abundance from mitochondrial utilization*, doi:[10.64898/2026.05.22.727209](https://doi.org/10.64898/2026.05.22.727209).

Ogasawara, E., Tani, H., Suzuki, C., Owada, Y., Ogata, M., Ishihara, N., Abe, T. et Nakada, K. (2026). **Effects of an indole chemical, mitochonic acid 5, in a mouse model of mitochondrial disease onset.** Sci Rep, doi:[10.1038/s41598-026-57342-3](https://doi.org/10.1038/s41598-026-57342-3).

Oh, J., Lee, K., Won, D., Lee, Y.-M. et Shin, J. I. (2026). **Genetic diagnosis of hereditary kidney disease in pediatric patients through whole-exome sequencing and mitochondrial DNA analysis.** Kidney Res Clin Pract, doi:[10.23876/j.krcp.25.394](https://doi.org/10.23876/j.krcp.25.394).

Okletey, J., Muench, M., Yu, C., Maresca, A., Carelli, V. et Tigano, M. (2026). *Mutations Causative of CPEO Differentially Engage Innate Immunity Sensors*, doi:[10.64898/2026.05.24.727547](https://doi.org/10.64898/2026.05.24.727547).

Olander, S., Karaman, S., Suomi, F., Aguilar, K., Zhaivoron, A., Nedergaard, M., Smeds, L., Tiihonen, J., Quintana, A., Hidalgo, J., Alitalo, K., Ala-Laurila, P., Ince-Dunn, G. et Suomalainen, A. (2026). **Loss of mitochondrial DNA helicase in retinal macroglia drives neovascular retinopathy.** EMBO Mol Med, doi:[10.1038/s44321-026-00438-0](https://doi.org/10.1038/s44321-026-00438-0).

Omar, A., Abg Kamaludin, D. P., Mohamed, W. A. S., Nordin, F. D. A., Mohamed, R., Razali, B. H., Ismail, I., Hock, N. L. et Jalil, J. A. (2026). **Screening and Stratification Utility of GDF-15 and FGF-21 in Individuals Evaluated for Suspected Mitochondrial Disease: A Malaysian Cohort Study.** Metabolites 16, 372, doi:[10.3390/metabo16060372](https://doi.org/10.3390/metabo16060372).

Piergentili, R., Vergallo, G. M., Marinelli, E., Pelagatti, E., Sechi, S., Furnari, M. L., Gullo, G. et Zaami, S. (2026). **Mitochondrial donation and human reproduction: Clinical, ethical and legal aspects.** Mitochondrion 91, 102175, doi:[10.1016/j.mito.2026.102175](https://doi.org/10.1016/j.mito.2026.102175).

Pinho, B. R., Duchon, M. R. et Oliveira, J. M. A. (2026). **Mitophagy: an emerging therapeutic target in mitochondrial diseases.** Biochem J 483, 1193-1220, doi:[10.1042/BCJ20260161](https://doi.org/10.1042/BCJ20260161).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Preston, G., Shamma, I., Pinto E Vairo, F., Ligezka, A., Aschoff, C. A. de M., Poswar, F., Schwartz, I. V. D., Kozicz, T. et Morava, E. (2026). **Reversible Metabolic and Liver Disease in Complex III Deficiency: Novel Variants Expand the Reported UQCRC2-Associated Phenotype.** Cells 15, 596, doi:[10.3390/cells15070596](https://doi.org/10.3390/cells15070596).

Prosper, C., Zereg, E., Chaussenot, A., Bannwarth, S., Lannes, B., Streichenberger, N., Kaphan, E., Nadaj-Pakleza, A., Villa, L., Sacconi, S., Masingue, M., Birgy, E., Francou, B., Ait-El-Mkadem Saadi, S., Fragaki, K., Paquis-Flucklinger, V. et Rouzier, C. (2026). **Challenging mtDNA tRNA variant guidelines: Emphasizing single-cell analysis through four novel variants.** Mitochondrion 90, 102170, doi:[10.1016/j.mito.2026.102170](https://doi.org/10.1016/j.mito.2026.102170).

Qin, L., Gan, D., Chen, Z., Xu, Z., Wu, M., Gao, B., Long, Y., Mou, X., Li, W., Yi, W. et Xiao, G. (2026). **Mitochondria transfer in tissue homeostasis and diseases.** Int J Biol Sci 22, 3144-3173, doi:[10.7150/ijbs.129709](https://doi.org/10.7150/ijbs.129709).

Ramón-Gómez, J. L., de Felipe, M., Balsells, S., Martínez Segura, G., Ruiz García, C. et Ortigoza-Escobar, J. D. (2026). **Management of Movement Disorders in Chronic Neurological Conditions and Palliative Care: A Retrospective Cohort Study.** Pediatr Neurol 179, 54-62, doi:[10.1016/j.pediatrneurol.2026.03.006](https://doi.org/10.1016/j.pediatrneurol.2026.03.006).

Reddy, S. B., Daru, A., Pande, V., Chalipat, S. et Sai, P. B. V. S. (2026). **COQ8A-related Primary Coenzyme Q10 Deficiency Mimicking Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Syndrome: A Pediatric Case Report and Review of Mitochondrial Mimics.** Ann Afr Med, doi:[10.4103/aam.aam_180_26](https://doi.org/10.4103/aam.aam_180_26).

Refrigeri, M., Tola, A., Mogavero, R., Pietracupa, M. M., Gionta, G. et Scatena, R. (2026). **Mitochondrial myopathy biomarkers.** Adv Clin Chem 133, 161-216, doi:[10.1016/bs.acc.2026.01.007](https://doi.org/10.1016/bs.acc.2026.01.007).

Reguera-Cabezas, M., Martínez-Pastor, F. et Soriano-Úbeda, C. (2026). **Current state of the art in the transmission of mitochondrial DNA pathogenic variants: reviewing preventive-therapeutic alternatives.** J Assist Reprod Genet, doi:[10.1007/s10815-026-03888-0](https://doi.org/10.1007/s10815-026-03888-0).

Rindell, N., Immonen, H. et Martikainen, M. H. (2026). **Prevalence and treatment of mitochondrial diabetes in Southwest Finland.** J Diabetes Metab Disord 25, 154, doi:[10.1007/s40200-026-01964-x](https://doi.org/10.1007/s40200-026-01964-x).

Rose, P. C., Rabie, H., de Lacy, R., Riordan, G., van der Watt, G., van Niekerk, M., van Toorn, R., Mokoto, T. et Meldau, S. (2026). **Neonatal HIV prophylaxis is associated with accelerated presentation and clinical progression of MPV17-related mitochondrial neurohepatopathy.** BMC Pediatr, doi:[10.1186/s12887-026-06984-3](https://doi.org/10.1186/s12887-026-06984-3).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Rubalcava-Gracia, D. et Larsson, N.-G. (2026). **Mammalian mtDNA gene expression: Concepts learned from in vivo models.** Biochim Biophys Acta Mol Cell Res 1873, 120158, doi:[10.1016/j.bbamcr.2026.120158](https://doi.org/10.1016/j.bbamcr.2026.120158).

Russell, N. D., Downie, J. M., Bromberg, M. B., Pulst, S. M. et Jorde, L. B. (2026). **Genetic contributions to mitochondrial dysfunction in amyotrophic lateral sclerosis etiology.** HGG Adv 7, 100614, doi:[10.1016/j.xhgg.2026.100614](https://doi.org/10.1016/j.xhgg.2026.100614).

Ryall, C., Chinnery, P. F. et van den Ameele, J. (2026). **Common Principles Underlie Mitochondrial DNA Heteroplasmy Dynamics in the Germline and Soma.** Annu Rev Genomics Hum Genet, doi:[10.1146/annurev-genom-120324-032239](https://doi.org/10.1146/annurev-genom-120324-032239).

Ryytty, S., Nurminen, K., Tiukuvaara, T., Mäkinen, P., Suomalainen, A. et Hämäläinen, R. H. (2026). **Patient specific regulation of metabolism and cell death pathways in m.3243A>G mutated iPS-cells.** Sci Rep 16, 19744, doi:[10.1038/s41598-026-43696-1](https://doi.org/10.1038/s41598-026-43696-1).

Sahayasheela, V. J., Noizumi, R., Lankadasari, M. B., Terada, T., Ooga, M., Kulkarni, A., Suzuki, S., Hidaka, T., Cai, L., Pandian, G. N., Bando, T., Reddi, A. R. et Sugiyama, H. (2026). **Mitochondrial-generated G-quadruplex-forming lncRNAs regulate heme homeostasis.** iScience 29, 116425, doi:[10.1016/j.isci.2026.116425](https://doi.org/10.1016/j.isci.2026.116425).

Sandmann, C., Gudapati, S., Mayr, J. A., Jamra, R. A., Kovacevic, A. et Syrbe, S. (2026). **Cardiomyopathy and mitochondrial encephalomyopathy in a female child associated with a heterozygous X-linked AIFM1 variant.** Mol Cell Pediatr 13, 34, doi:[10.1186/s40348-026-00246-z](https://doi.org/10.1186/s40348-026-00246-z).

Sapuppo, A., Privitera, G. F., Sortino, V., Pavone, P., Polizzi, A., Ruggieri, M. et Falsaperla, R. (2026). **Diagnosis of pediatric mitochondrial diseases via targeted next-generation sequencing (NGS): real-world data with the Blueprint Genetics® platform.** Orphanet J Rare Dis 21, 143, doi:[10.1186/s13023-026-04213-9](https://doi.org/10.1186/s13023-026-04213-9).

Savvidou, A., Sofou, K., Thunström, S., Ygberg, S., Eklund, E. A., Naess, K., Kollberg, G. et Darin, N. (2026). **A Nationwide Study of Pyruvate Dehydrogenase Complex Deficiency in Sweden: Epidemiology, Genotype-Phenotype Correlations, and Survival.** Neurology 106, e214924, doi:[10.1212/WNL.0000000000214924](https://doi.org/10.1212/WNL.0000000000214924).

Schechter, D. R., Tinker, R. J., O'Connell, P., Pang, J., SzeKing Lee, S., Kars, M. E., Guvenek, A., Preuss, M., Itan, Y., Morava, E., Kozicz, T., Hirano, M., Naini, A. et Ganesh, J. (2026). **Enrichment of Rare Mitochondrial DNA Variants Among Individuals With Kidney Disease Reveals Undiagnosed Mitochondrial Disease.** Kidney Int Rep 11, 106578, doi:[10.1016/j.ekir.2026.106578](https://doi.org/10.1016/j.ekir.2026.106578).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Semcesen, L. N., Ball, M., Hock, D. H., Kaye, J., Woods, A., De Jong, L., MitoMDT Diagnostic Network for Genomics and Omics, Christodoulou, J., Thorburn, D. R., Compton, A. G., Stroud, D. A. et Liebelt, J. (2026). **Antenatal Presentation of MRPS22-Related Mitochondrial Disease Confirmed With Rapid Proteomics**. JIMD Rep 67, e70092, doi:[10.1002/jmd2.70092](https://doi.org/10.1002/jmd2.70092).

Sharma, G., Srivastava, A., Rockman-Greenberg, C. et Dhingra, S. (2026a). **Generation of a patient-derived iPSC line from a clinically diagnosed MELAS case carrying the mtDNA m.3243A > G variant**. Stem Cell Res 95, 104038, doi:[10.1016/j.scr.2026.104038](https://doi.org/10.1016/j.scr.2026.104038).

Sharma, G., Srivastava, A., Rockman-Greenberg, C. et Dhingra, S. (2026b). **iPSC generation from PBMCs of a MELAS patient for mitochondrial dysfunction studies**. Stem Cell Res 94, 103992, doi:[10.1016/j.scr.2026.103992](https://doi.org/10.1016/j.scr.2026.103992).

Shen, S., Xu, Y., Kober, D. L. et Wang, J. (2026). **Mechanisms of human mitochondrial leaderless mRNA translation initiation**. Nat Commun 17, 4887, doi:[10.1038/s41467-026-71535-4](https://doi.org/10.1038/s41467-026-71535-4).

Shi, R., Falabella, M., Aref, J., Hanna, M. G., Minczuk, M., Viscomi, C. et Pitceathly, R. D. S. (2026). **Emerging therapeutic strategies for mitochondrial DNA-related diseases**. Cell Rep Med 7, 102841, doi:[10.1016/j.xcrm.2026.102841](https://doi.org/10.1016/j.xcrm.2026.102841).

Shibata, K.-I., Mukai, T., Nakagaki, H. et Nagano, S. (2026). **A case of a spinal cord involvement in an adult mitochondrial disease with an m.3243A>G**. Rinsho Shinkeigaku 66, 422-423, doi:[10.5692/clinicalneuroL.cn-002220](https://doi.org/10.5692/clinicalneuroL.cn-002220).

Siragusa, S. L., Blando, S., Fiorini, C., Pasti, A. P., Ormanbekova, D., Casadei, F., Morandi, L., Pegoraro, E., Liguori, R., Carelli, V., La Morgia, C., Caporali, L. et Valentino, M. L. (2026). **Expanding the landscape of tRNA pathogenic variants in mitochondrial DNA**. Brain Commun 8, fcag178, doi:[10.1093/braincomms/fcag178](https://doi.org/10.1093/braincomms/fcag178).

Song, K., Yoon, M. K., Yang, W., Chang, J. Y., Kang, D.-W., Kwon, S. U. et Kim, B. J. (2026). **Cerebral vasodilation and lesion patterns in stroke-like episodes of MELAS: a quantitative angiographic investigation**. Quant Imaging Med Surg 16, 361, doi:[10.21037/qims-2025-1-2735](https://doi.org/10.21037/qims-2025-1-2735).

Stefanetti, R. J., Pizzamiglio, C., Blain, A. P., Russell, O. M., Alcock, L., Hudson, G., Newman, J., Thomas, N., Warren, C., Su, H., Tuppen, H. A. L., Brown, P., Houghton, D., Hunter, H., Lim, A. Z., Ng, Y. S., Feeney, C., Skorupinska, I., Germain, L., Bugiardini, E., Hanna, M. G., McFarland, R., Pitceathly, R. D. S. et Gorman, G. S. (2026). **Mavodelpar in patients with primary mitochondrial myopathy: a phase 1 trial**. Sci Rep, doi:[10.1038/s41598-026-43287-0](https://doi.org/10.1038/s41598-026-43287-0).

Stern, S., Crisamore, K., Patton, J., Schuck, R. et Pacanowski, M. (2026). **From Pharmacodynamic Biomarker to Evaluating Treatment Response: Biomarkers in Primary Mitochondrial Diseases**. Clin Transl Sci 19, e70634, doi:[10.1111/cts.70634](https://doi.org/10.1111/cts.70634).



Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Takai, Y., Yamagami, A., Inoue, K., Ishikawa, H. et Wakakura, M. (2026a). **Branch retinal vein occlusion in Leber hereditary optic neuropathy with onset at age 50 years or older: frequency and clinical characteristics.** Jpn J Ophthalmol, doi:[10.1007/s10384-026-01364-x](https://doi.org/10.1007/s10384-026-01364-x).

Takai, Y., Yamagami, A., Iwasa, M., Inoue, K., Yasumoto, R., Ishikawa, H. et Wakakura, M. (2026b). **Reply To: Comments on « Age-Associated Differences in Optic Disc Findings of Leber's Hereditary Optic Neuropathy ».** Neuroophthalmology 50, 294-295, doi:[10.1080/01658107.2026.2642123](https://doi.org/10.1080/01658107.2026.2642123).

Tamashiro, H., Ishikawa, K. et Nakada, K. (2026). **Comparative analysis of muscle pathologies and metabolic signaling in mouse models of mitochondrial dysfunction.** Sci Rep 16, 17722, doi:[10.1038/s41598-026-48532-0](https://doi.org/10.1038/s41598-026-48532-0).

Taylor, M., Halicki, M. et Chazot, P. (2026). **Cholesterol in Mitochondrial Diseases-Friend or Foe?** Int J Mol Sci 27, 4353, doi:[10.3390/ijms27104353](https://doi.org/10.3390/ijms27104353).

Tengan, C. H., Oliveira, A. S. B., Carvalho, A. A. de S., Souza, C. D. S. de, Sobreira, C. F. da R., Zanoteli, E. et Silva, H. C. A. da (2026). **Rhabdomyolysis: a narrative review.** Arq Neuropsiquiatr 84, 1-13, doi:[10.1055/s-0046-1824437](https://doi.org/10.1055/s-0046-1824437).

Torraco, A., Alston, C. L., Barcia, G., Verrigni, D., Rizza, T., Di Nottia, M., Altobelli, A., Martinelli, D., Diodato, D., Efthymiou, S., Kose, M., Kriouile, Y., Lim, A. Z., Morlino, S., Siri, B., Saadi, N. W., Novelli, A., Houlden, H., Dionisi-Vici, C., McFarland, R., Rötig, A., Bertini, E., Taylor, R. W. et Carrozzo, R. (2026). **Neurological manifestations and genotype-phenotype correlations in NDUFAF6-associated mitochondrial disease.** Brain Commun 8, fcag095, doi:[10.1093/braincomms/fcag095](https://doi.org/10.1093/braincomms/fcag095).

Tsai, N.-C., Liang, Y.-C. et Lan, K.-C. (2026). **Response to « Molecular Diagnostic Platforms for Mitochondrial Diseases by Conventional and Long-Read Sequencing: Missing pieces ».** Biomed J 100991, doi:[10.1016/j.bj.2026.100991](https://doi.org/10.1016/j.bj.2026.100991).

Van de Vondel, L., Lee, G. S., De Winter, J., Matsuzaki, S., Sandoval, A., Ramirez, J. F., Monticelli, A., Lee, S., Horvath, R., de Bleecker, J., Züchner, S., Humphries, K. M., Baets, J. et Yoon, W. H. (2026). **Heterozygous OGDH Variants Are Involved in Peripheral Neuropathy With Ataxia and Optical Atrophy.** JIMD Rep 67, e70103, doi:[10.1002/jmd2.70103](https://doi.org/10.1002/jmd2.70103).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Van Hove, J. L. K., Friederich, M. W., Van Hove, R. A., Lee, J. C., Knight, K. M., Donovan, T. E., Silveira, L., Ganetzky, R. D., Hirano, M., Abdenur, J., Butler, M. G., Cassiman, D., Cohen, B. H., Elsea, S. H., Enns, G. M., Gahl, W. A., Gavrilova, R., Geddes, G. C., Glamuzina, E. E., Goldstein, A., Haas, R. H., Khan, A., Kripps, K. A., Larson, A. A., Lehman, A. N., Lichter-Konecki, U., Mayr, J. A., Morava, E., Peterson, J. T., Rosenfeld, J. A., Saneto, R. P., Scaglia, F., Shelkowitz, E., Simon, M., Smet, J. E. G., Smith, W. E., Soler-Alfonso, C., Tarnopolsky, M., Van Coster, R. N. A., Vanlander, A. V., Vermeersch, P., Vockley, J., Wigby, K., Wolfe, L. A., Wortmann, S. B. et Yang, J. H. (2026). **The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease.** doi:[10.64898/2026.06.12.26355546](https://doi.org/10.64898/2026.06.12.26355546).

Volk, M., Maver, A., Vidmar, M. J., Trošt, N., Višnjar, T., Fakin, A., Kovač, L., Habjan, M. Š., Malinar, L., Pajić, S. P., Jerman, U. D., Romih, R., Hawlina, M. et Peterlin, B. (2026). **Discovery of PHB1 as a Novel Candidate Gene in Dominant Optic Atrophy.** Clin Genet 110, 165-171, doi:[10.1111/cge.70174](https://doi.org/10.1111/cge.70174).

Wan, Q., Ding, Y., Liu, W. et Yang, K. (2026). **Effects of exercise training on skeletal muscle function in patients with mitochondrial myopathy: a systematic review.** Front Sports Act Living 8, 1710264, doi:[10.3389/fspor.2026.1710264](https://doi.org/10.3389/fspor.2026.1710264).

Wang, K., Li, S., Zhang, Y. et Guan, M. (2026). **[The « Triple-hit » pathogenic mechanism of Leber hereditary optic neuropathy].** Zhejiang Da Xue Xue Bao Yi Xue Ban 1-9, doi:[10.3724/zdxbyxb-2025-0868](https://doi.org/10.3724/zdxbyxb-2025-0868).

Wang, L.-T. et Jhuang, H.-Y. (2026). **Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies.** Biomed Pharmacother 201, 119699, doi:[10.1016/j.biopha.2026.119699](https://doi.org/10.1016/j.biopha.2026.119699).

Weissig, V. (2026). **170 Years of Mitochondrial Research and the Emergence of Mitochondrial Medicine.** J Clin Pharmacol 66, e70209, doi:[10.1002/jcph.70209](https://doi.org/10.1002/jcph.70209).

Wesół-Kucharska, D., Kaczor, M. A. et Emczyńska-Seliga, E. E. V. (2026). **Benefits and adverse effects of ketogenic diet treatment in pediatric patients with inborn errors of metabolism.** Adv Clin Exp Med, doi:[10.17219/acem/219994](https://doi.org/10.17219/acem/219994).

Wortmann, S. B., de Brouwer, A. P. et Wevers, R. A. (2026). **SERAC1 Deficiency.** In: **GeneReviews®**, Éd. Adam, M. P., Bick, S., Mirzaa, G. M., Pagon, R. A., Wallace, S. E., et Amemiya, A. University of Washington, Seattle, Seattle (WA), URL: <http://www.ncbi.nlm.nih.gov/books/NBK195853/> [Consulté le juillet 2026].

Wu, B., Lv, J., Shen, T., Wen, B. et Wang, T. (2026). **Mild-cerebellar ataxia due to impaired mitochondrial function caused by the MSTO1 variations.** Front Neurosci 20, 1775132, doi:[10.3389/fnins.2026.1775132](https://doi.org/10.3389/fnins.2026.1775132).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Wu, H., Wang, Y. et Kong, Q. (2026). **Phenotypic heterogeneity within twins with MELAS with epilepsy: Case report.** *Medicine (Baltimore)* 105, e47264, doi:[10.1097/MD.00000000000047264](https://doi.org/10.1097/MD.00000000000047264).

Xia, J., Liao, K., Wang, J., Lu, M., Mu, Y. et Lin, Y. (2026). **From Initiation to Elongation: eIF3 as a Dual-Phase Guardian of Mitochondrial Integrity and Protein Homeostasis in Skeletal Muscle.** *FASEB J* 40, e71808, doi:[10.1096/fj.202600039R](https://doi.org/10.1096/fj.202600039R).

Xia, Y., She, Y., Zhao, R. et Zhang, Y. (2026). **MNGIE with TYMP and POLG variants presenting as decade-long capsule retention: A case report.** *Neurol Sci* 47, 521, doi:[10.1007/s10072-026-09131-z](https://doi.org/10.1007/s10072-026-09131-z).

Xie, W., Murdock, D. G. et Wallace, D. C. (2026). **Mitochondria and Qi: Merging eastern and western medicine.** *Pharmacol Res* 229, 108243, doi:[10.1016/j.phrs.2026.108243](https://doi.org/10.1016/j.phrs.2026.108243).

Xu, W., Shen, Y., Liu, X., Leng, F. et Liu, Y. (2026). **AXOLOTL: an accurate method for detecting aberrant gene expression in rare diseases using coexpression constraints.** *Bioinformatics* 42, btag255, doi:[10.1093/bioinformatics/btag255](https://doi.org/10.1093/bioinformatics/btag255).

Xu, Y., Gao, X., Xu, S., Jian, L., Shi, J., Zhao, Y., Wang, Y., Yang, Y., Yuan, Y., Dai, Q., Zhang, Q., Li, J. et Zhang, L. (2026). **Perilipin 5 enhances glycogen storage and mitigates excessive fatty acid oxidation in skeletal muscle to alleviate mitochondrial impairment.** *Biochim Biophys Acta Mol Cell Res* 1873, 120146, doi:[10.1016/j.bbamcr.2026.120146](https://doi.org/10.1016/j.bbamcr.2026.120146).

Yang, Q., Zhang, Q., Zhou, X., Qin, Z., Liang, X., Yi, Sheng, Zhang, S., Lu, W., Yi, Shang et Luo, J. (2026). **Clinical and genetic analysis of Chinese patients with Leigh syndrome caused by biallelic loss-of-function variants of the NDUFAF6 gene.** *Front Neurol* 17, 1778719, doi:[10.3389/fneur.2026.1778719](https://doi.org/10.3389/fneur.2026.1778719).

Yang, Y.-L. et Guo, L. (2026). **Cell Death in Skeletal Muscle Diseases: Diverse Roles and Pathological Processes.** *Cells* 15, 744, doi:[10.3390/cells15090744](https://doi.org/10.3390/cells15090744).

Yangzom, T., Chen, A., Lundberg, B. C. et Liang, K. X. (2026). **Nicotinamide riboside reduces glial inflammation and boosts mitochondrial function.** *Int J Biol Sci* 22, 6035-6063, doi:[10.7150/ijbs.119262](https://doi.org/10.7150/ijbs.119262).

Yin, Y., Wang, A., Dong, Q., Zhang, Z., Bu, Q., Wang, R. et Chang, Q. (2026). **A high-throughput screening platform to facilitate treatment development in Rett syndrome.** *Front Neurol* 17, 1759410, doi:[10.3389/fneur.2026.1759410](https://doi.org/10.3389/fneur.2026.1759410).

Yoon, C. S., Ko, J. R., Park, N., Park, S. H., Kim, H. K. et Han, J. (2026). **Binaphthoquinone attenuates myofibroblast transition of human ventricular cardiac fibroblasts in vitro via mitochondrial modulation under diabetic conditions.** *Korean J Physiol Pharmacol*, doi:[10.4196/kjpp.25.434](https://doi.org/10.4196/kjpp.25.434).

Mitochondrial disorders : The Essential

MMITO-2026-2 from april 1st to june 30, 2026

Yoshida, C., Kubota, A., Kawamoto, N., Takahashi, K., Yano, S., Komaki, S., Maeda, M., Naruse, H., Matsukawa, T., Hamada, M., Satake, W. et Toda, T. (2026). **A de novo TWNK Variant Mimicked Sporadic Chronic Progressive External Ophthalmoplegia**. Intern Med, doi:[10.2169/internalmedicine.7395-26](https://doi.org/10.2169/internalmedicine.7395-26).

Yoshida, R., Mitsuno, R., Azegami, T., Yamaguchi, S. et Hayashi, K. (2026). **Response to « Before taurine is recommended for stroke-like episodes in m.3243A > G carriers, its efficacy must be demonstrated by appropriate studies »**. CEN Case Rep 15, 67, doi:[10.1007/s13730-026-01112-7](https://doi.org/10.1007/s13730-026-01112-7).

Yoshimi, A., Cario, H., Timmermann, K., Kontny, U., Lobitz, S., Odenthal, H. S., Schmid, I., Seitz, B., Höll, T., Lücke, T., Borkhardt, A., Strauß, G., Hohnacker, A., Metzler, M., Karall, D., Noellke, P., Niemeyer, C. M. et Grünert, S. C. (2026). **Progressive short stature in Pearson syndrome and the impact of organ failure**. Mol Genet Metab 148, 110160, doi:[10.1016/j.ymgme.2026.110160](https://doi.org/10.1016/j.ymgme.2026.110160).

Zakirova, E., Sergeeva, S., Morozova, K., Kiseleva, E., Tanaka, M., Mazunin, I. et Orishchenko, K. (2026). **Specific elimination of m.8993T>G mitochondrial haplotype in NARP cybrid cells by CRISPR-Cas9 system**. Sci Rep 16, 19745, doi:[10.1038/s41598-026-49007-y](https://doi.org/10.1038/s41598-026-49007-y).

Zhang, X.-W., Ye, X.-M., Wang, R., Guo, Y.-D., Li, L., Chen, Y., Liu, T.-T., Zhou, X.-Q., Wang, Y.-Q., Li, Z.-Y., Lu, Z.-Y., Du, Z.-Y., Zhou, W., Han, B., Tu, P.-F., Chen, Q.-X., Zheng, C.-H. et Zeng, K.-W. (2026). **Triose phosphate isomerase 1 remodels mitochondrial cristae ultrastructure to rewire microglial immunometabolism against ischemic stroke**. Nat Commun, doi:[10.1038/s41467-026-72779-w](https://doi.org/10.1038/s41467-026-72779-w).

Zhang, Yingfan, Parry, H. A., Reyes, L., Shamoun, A., Sun, J., Liu, C., Springer, D., Noguchi, A., Nakamori, S., Aponte, A. M., Munasinghe, J., Covian, R., Murphy, E. et Glancy, B. (2026). **Loss of TMEM65 in mice causes mitochondrial disease mediated by mitochondrial Ca²⁺**. Nat Commun 17, 5203, doi:[10.1038/s41467-026-71761-w](https://doi.org/10.1038/s41467-026-71761-w).

Zhang, Yong, Yao, S.-Y., Li, J., Yu, T., Liu, H., Zhu, N., Peng, G.-X., Zheng, W.-Q., Ma, C.-R., Wang, E.-D., Song, C. et Zhou, X.-L. (2026). **Molecular pathogenesis and gene therapy-based intervention of GTPBP3-related mitochondrial disease**. Nat Commun 17, 5033, doi:[10.1038/s41467-026-71750-z](https://doi.org/10.1038/s41467-026-71750-z).

Zhuang, Y., Liu, X., Shen, Y., Wang, Q., Lin, Z., Zeng, Q., Chen, X., Jiang, L., Yao, S. Q. et Ge, J. (2026). **Reversible one-step acylation facilitates mitochondrial delivery of functional RNA**. Chem Sci, doi:[10.1039/d6sc01497f](https://doi.org/10.1039/d6sc01497f).